MOUNTAIN VIEW, CA–(Marketwire – August 2, 2010) –  NCP engineering, Inc. today announced that American Hospice has selected the NCP Secure Enterprise Solution to protect patient data reported by its 180 home healthcare employees. Staff now use NCP’s remote access software to connect their Windows Mobile-based devices to American Hospice’s network, and access and update patient information in real time from anywhere, securely and in full compliance with HIPAA regulations.

NCP’s technology also allows American Hospice and its home healthcare staff to maximize efficiency and improve patient care while on the road. Previously, employees’ recordkeeping was a manual, paper-based system, which often took a week or more to process. Today, staff can safely check their patients’ medical records and home visit schedules, track their travel mileage and immediately provide patient status updates. The NCP Secure Enterprise Solution secures all of the information on the devices themselves and while in transit to the hospice’s network, a key HIPAA requirement.

Key Facts:

• American Hospice is a national leader in the delivery of hospice services. Its interdisciplinary teams, including physicians, nurses, hospice aides, pharmacists, medical social workers, spiritual care specialists, bereavement counsellors and hospice volunteers, serve several thousand patients every day.

• The NCP Secure Enterprise Solution was rolled out in May 2010, with NCP engineering meeting American Hospice’s five-day deployment deadline — taking only three days.

• 180 home healthcare employees stationed throughout Arizona, Georgia, New Jersey, Oklahoma and Virginia use NCP’s one-click IPsec VPN client to synchronize and securely transmit patient data from their Windows Mobile-based devices to the hospice’s server.

• The NCP Secure Enterprise Management System provides American Hospice’s IT staff with a single point of administration for the hospice management company’s entire VPN network, as well as full NAC management. Network administrators can easily control user and device provisioning, and distribute plug-in updates and configuration settings.

Supporting Quotes:

• “Our team tested several VPN solutions, but the NCP Secure Enterprise Solution was the only one able to fully meet our remote access needs,” said Fred Cruz, IT director, American Hospice. “We were extremely impressed with the company’s technology and support during the deployment phase. The stability to ensure a secure communications environment for our healthcare staff has become a cornerstone of our mission to provide the highest quality care to our patients and their families.”

• “American Hospice required a complete, flexible and user-friendly VPN solution for its mobile workforce,” said H. Peter Felgentreff, president and CEO, NCP engineering, Inc. “We are pleased to have fit the bill, and helped the healthcare customer not only rethink its secure remote access but also maximize employee productivity and reduce its operational costs.” 

Resources:

• For more information about American Hospice, please visit www.americanhospice.com.

• For more information about NCP engineering, please visit www.ncp-e.com. Reach the company on its blog, VPN Haus, or on Twitter.

• To learn how NCP engineering enables its customers to rethink remote access with its “Next Generation Network Access Technology”, please visit http://www.ncp-e.com/en/solutions/rethink-remote-access.html.

Tags:
NCP engineering, American Hospice, remote access, VPN, healthcare, HIPAA, security, network, enterprise

About NCP engineering, Inc.
Since its inception in 1986, NCP engineering has delivered innovative software that allows enterprises to rethink their secure remote access, and overcome the complexities of creating, managing and maintaining network access for staff.

NCP’s award-winning product line spans the spectrum of remote access, from IPSec / SSL VPN to endpoint firewalls and network access control (NAC) functions. The company’s products support organizations with complex remote user needs, who want to leverage the latest end-devices to increase staff productivity, reduce network administration and adapt policy changes on-the-fly. Each solution is interoperable with existing third-party software or hardware.

Headquartered in the San Francisco Bay Area, the company serves 30,000-plus customers worldwide throughout the healthcare, financial, education and government markets, as well as many Fortune 500 companies. NCP has established a network of national and regional technology, channel and OEM partners to serve its customers. For more information, visit www.ncp-e.com.

id=”nav_links”>

KANKAKEE, IL–(Marketwire – August 2, 2010) – Riverside Medical Center’s recent investment in a new state-of-the art Interventional Radiology (IR) system, greatly expands the advanced services it can now offer the Kankakee Illinois healthcare community. Riverside saw an opportunity to re-engineer the patient experience and improve workflow around the Kankakee County hospital and they jumped at the chance.

Riverside’s IR room underwent a complete remodel and expansion. The new room, which cost nearly $2 million, features positive air pressure making it operating room compatible. The room now uses Toshiba’s Infinix-i-x-ray system. This new imaging system has greatly impacted the quality of care and safety for the patient that this south Chicago healthcare giant can provide. Being able to control the amount of radiation administered is extremely important to the patient, radiologists and staff. This new system equips the physicians and radiologists with a comprehensive dose management package that allows for greater control, superior precision and less exposure to radiation. 

The equipment, which was once controlled in a separate room, can now be completely controlled in one area, allowing the staff to remain with the patient for added safety. In addition, Riverside Medical Center has paired the x-ray system with Toshiba’s 12″x12″ mid-sized flat panel detector. Together, they offer a wider field-of-view and provide increased visualization and optimal access, helping radiologists more quickly and accurately diagnose and treat patients.

Radiologists are now also able to view the patient’s images on a live feed and can immediately pull up a patient’s previous scans and display them on the monitors for comparison. Doctors now have immediate access to angiograms, physiological monitoring, CT and MRI scans, and many other imaging or patient specific data that can be displayed throughout the entire procedure. Clearer, sharper images and enhanced system utilization are all important features of today’s interventional radiology room.

Previously, a patient was literally moved in many different directions in order to perform the procedure. With Riverside’s advanced new technology, the unit moves to the patient. When combining the five-axis positioner with the tilting and cradling features of the table, physicians are able to obtain optimal angles for interventional procedures without re-positioning the patient. With these modern updates, Riverside is caring for patients in new and exciting ways.

To learn more about the quality services offered by Riverside Medical Center, visit www.RiversideMC.net or call (815) 933-1671.

Click here to see all recent news from this company

SPRINGFIELD, OH–(Marketwire – August 2, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, has closed on a previously announced agreement to lease five privately held nursing homes in South Georgia that is expected to more than double its revenue.

The five facilities have been leased under a five-year term from the owner, with an extension option for an additional five years. The facilities have on aggregate 615 beds that generate approximately $35 million in annualized revenue.

AdCare’s upfront cost for the transaction was $700,000 in cash, plus legal and accounting closing costs. At closing, the company assumed approximately $1.3 million in negative working capital and purchased for $2 million approximately $5.5 million in existing receivables due to these facilities. In addition, AdCare provided the lessor $1.16 million, comprised of the first month’s lease payment and a security deposit that includes an amount equal to two months lease payment.

With the close of this transaction, AdCare estimates its revenue run-rate will exceed $61 million annually, representing an increase of more than 120% over the company’s 2009 revenues.

“This lease is the first major transaction we closed since we began our acquisition campaign at the end of last year,” said Chris Brogdon, AdCare’s vice chairman and chief acquisitions officer. “We expect these facilities to be very profitable for AdCare, especially as they come under our more capable management and benefit from the economies of scale we bring to the table.”

AdCare also reported it signed an agreement to lease an additional five nursing homes in Georgia that produce annualized revenues of approximately $37 million, which it plans to close on September 30, 2010.

“We are also now moving quickly toward closing the other two acquisitions we announced in the first half of 2010,” noted Brogdon. “As we have outlined in our M&A strategy, we are also continuing to evaluate foreclosures and other poorly run facilities that we can secure at below-market prices, as well as target acquisitions of both profitable and turnaround properties to grow our business.”

Brogdon joined AdCare last September when the company announced a new M&A growth strategy to build upon its strong reputation for operational efficiency and high-quality living environments.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law, which can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “plans,” “anticipates” or similar expressions. Statements in this announcement that are forward-looking include, but are not limited to, statements that with the closing of this transaction, AdCare estimates its revenue run-rate will exceed $61 million annually, representing an increase of more than 120% over the company’s 2009 revenues; that the leased facilities mentioned in this release will be very profitable for AdCare; that it plans to close the newly announced additional five leases on September 30, 2010; and that the company is moving quickly toward closing the other two acquisitions it announced in the first half of 2010. Such forward-looking statements reflect management’s beliefs and assumptions, and are based on information currently available to management. The forward-looking statements involve known and unknown risks that may make the results, performance or achievements of the company differ materially from those expressed or implied in such statements. Such factors are also identified in the public filings made by the company with the U.S. Securities and Exchange Commission, and they include, but are not limited to, the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs, and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

CARMEL, IN–(Marketwire – August 2, 2010) –  Clinical Architecture today announced that UMass Memorial Health Care, the largest healthcare system in Central and Western Massachusetts, has selected Clinical Architecture’s Symedical™ interoperability solution. UMass Memorial is using Symedical™ to re-code patient data from various locations and terminologies into a central data repository using a single terminology set. “Merging patient data from disparate sources is a significant undertaking,” said John Poikonen, PharmD, Director of Clinical Informatics at UMass Memorial Medical Center. “Symedical has proven to be a pragmatic and efficient tool that allows us to focus on accuracy.”

Providing the highest quality of care requires access to a consistently accurate representation of the patient’s clinical context. Symedical™ enables clinical applications to maintain the continuity of meaning by sharing patient information as actionable discrete data. “It is no longer enough to offer read only access to medical records stored in various places throughout the healthcare enterprise,” said Charlie Harp, Chief Executive Officer of Clinical Architecture. “We’re pleased to be working with UMass Memorial as they leverage Symedical to deliver a more meaningful and actionable information exchange.”

About Clinical Architecture

Clinical Architecture specializes in meeting the integration and interoperability needs of healthcare through niche consulting and application development. The company was formed around the extensive clinical integration experience of its staff and has consistently succeeded in addressing complex problems with effective pragmatic solutions. The company is located just north of Indianapolis in Carmel, Indiana. For additional information on Clinical Architecture, contact John Wilkinson at (317) 580-8417 or visit www.clinicalarchitecture.com. Informative discussions of interoperability topics are available at the company’s Healthcare IT Blog; www.clinicalarchitecture.com/healthcare_technology_informatics_blog/.

About UMass Memorial Health Care

UMass Memorial Health Care is Central Massachusetts’ largest not-for-profit health care delivery system, covering the complete health care continuum with UMass Memorial Medical Center, its academic medical center, member and affiliated community hospitals, freestanding primary care practices, ambulatory outpatient clinics, home health agencies, hospice programs, a rehabilitation group and mental health services. UMass Memorial is the clinical partner of the University of Massachusetts Medical School. Visit www.umassmemorial.org for additional information. Follow UMass Memorial on Twitter at http://twitter.com/umassmemorial.

IRVING, TX–(Marketwire – August 2, 2010) – VHA Inc., the national health care network, will showcase its VHA SupplyLYNX™ portal and its array of analytics offerings at the annual meeting of the Association for Healthcare Resource & Materials Management Conference on August 1-4, in Denver.

VHA SupplyLYNX offers hospitals the ability to analyze every aspect of their purchasing activities for both products and services and gives them the data they need to accelerate the pace at which hospitals can reduce spending and maximize contract savings.

“VHA SupplyLYNX enables hospitals to fully optimize data throughout the organization and delivers unparalleled insight into the hospital’s performance,” said Scott Downing, executive vice president, Supply Chain Management at VHA. “Cost reduction is a daily focus and is essential to offset anticipated cuts in Medicare reimbursement that will decrease hospital revenues and potentially stifle the bottom line.”

In addition to the recently introduced VHA SupplyLYNX Web portal, attendees can participate in demonstrations of VHA PriceLYNX™ 2.0, the industry’s leading price benchmarking service. VHA PriceLYNX provides benchmarking analysis that arms decision makers with factual information that enables the organization to view long- and short-term market trends and respond to immediate price fluctuations. Ultimately, this information better equips the purchasing team during vendor negotiations. From January 2009 through June 2010, members using VHA PriceLYNX have identified an average savings of $4 million per quarter. 

AHRMM marks the public debut of VHA PriceLYNX mobile. VHA anticipates that mobile access via devices such as smart phones will give hospital personnel the opportunity to make faster decisions when it comes to switching products or accessing lower pricing on the products they already purchase. VHA recently launched its VHA SupplyLYNX mobile platform, built in conjunction with McLean, Va.-based MicroStrategy, to provide mobile access to its suite of analytical products and services. 

“Beginning with our leadership around data standards and e-commerce in 2001, VHA has led other analytics competitors by providing accurate, timely and actionable supply chain information to members, backed by the largest data set in health care,” continued Downing. “What sets us apart is our core belief in price transparency, a data warehouse that provides superior accuracy and a categorization methodology that ensures quality reporting every time.”

About VHA — VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. In 2009, VHA delivered record savings and value of $1.47 billion to members. Formed in 1977, through its 16 regional offices, VHA serves more than 1,400 hospitals and more than 28,000+ non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

GILBERT, AZ–(Marketwire – August 2, 2010) – As your boss reminds you that this is your third sick day in two months due to your “back pain excuse,” you hang up the phone frustrated. You aren’t playing hooky. You’d honestly rather be at work than flat on your back in pain. But taking painkillers makes it hard for you to function properly — and it merely masks the pain, instead of solving the problem. If only there was a solution that didn’t involve a knife and more time off work.

“When I treat patients with the one-two punch of spinal decompression and deep tissue laser therapy, they are able to return to their favorite activities, such as gardening, walking, dancing and tennis,” says Brian Self, D.C., a chiropractor with Arizona Pain & Wellness Centers. “And with 6.5 million people stuck in bed each day because of back pain, literally millions could benefit from this affordable, effective, permanent pain relief. While both procedures require multiple visits, most patients feel relief from their pain after their first few sessions.”

Spinal decompression is a revolutionary new technology that treats the symptoms of disc herniations, disc degeneration, sciatica and low back and neck pain. Patients simply lie on their backs while a specialized belt is placed comfortably around their waist. An advanced computer system is then set to focus on each patient’s specific problem area. As disc bulges or herniations are drawn in, or as the discs begin to regenerate, pressure is taken off the nerves and surrounding structures relieving the patient of pain and inflammation. In fact, Dr. Self says that the spinal decompression treatments are so gentle; he’s had patients become so relaxed, they fall asleep during it.

Most patients undergoing spinal decompression will also receive deep tissue laser therapy; because Dr. Self has found that these two treatments work best in tandem. “Our deep tissue laser works by flooding the tissues with photons, energizing the damaged cells and increasing circulation to the painful area,” he says. “This produces a cascade of healing responses in your body, reducing inflammation, thereby reducing or even eliminating your pain. There are no known side effects, it’s noninvasive and nonsurgical — and treatment simply feels like a deep, gentle warmth.”

To put an end to your neck and back pain without medications, injections or surgery, visit www.arizonapainandwellness.com

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 30, 2010) –  Increased demand for testing, new technologies and emerging markets have trumped the economic situation in the world in vitro diagnostics (IVD) market, according to the seventh edition of Kalorama Information’s biennial report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” The healthcare market research publisher reported a $44.3 billion market in 2009, and expects growth to be at a rate of six percent for the next five years. 

According to Kalorama the market has already weathered price declines and as a result developed innovative technologies and approaches. This has dulled the impact of a recession which has hurt other industries. Digital pathology, multiplex assays, automation and test service commercialization represent areas where the industry has developed new approaches. The market changes described in the report were on display at the American Association for Clinical Chemistry (AACC) convention in Anaheim, CA this week.

“The convention reflected what we’ve said in the report; that despite economic hard times, the IVD industry is on an upswing,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and author of the study. “A number of world events bode well for the future of testing.”

Trends such as the use of biomarkers and molecular approaches to testing have only increased since the last edition of the report. Consolidation has been a factor in an industry that is dominated by Roche, Siemens, and Abbott. The report notes that 72 percent of the revenue in 2009 was earned by just 18 companies. This hasn’t stopped scores of new companies with unique approaches from competing in diagnostics, according to Kalorama.

The report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition,” has more information on segment market sizes, forecasts, company analyses, and test product development. The report can be found at Kalorama Information at: http://www.kaloramainformation.com/redirect.asp?progid=79398&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

OAKBROOK TERRACE, IL–(Marketwire – July 30, 2010) –  Each year, millions of people — from elderly nursing home residents to hospitalized children to women who have just given birth — are injured by falls in health care facilities and homes. The Joint Commission today launched a national campaign to help Americans reduce the risk of falling.

The new education campaign, which is part of The Joint Commission’s award-winning Speak Up™ program, recognizes that falls are a serious problem. Statistics from the Centers for Disease Control and Prevention (CDC) show that falls are the second leading cause of injury-related deaths for people ages 65 and older, and are the most common cause of injuries and hospital admissions among the elderly. (Source: CDC, NCHS. Mortality Data Tapes. Hyattsville, MD: the Center, 1998.) Reducing injuries, disabilities and deaths from falls has even been included as part of the Healthy People 2010 program. The national Healthy People 2010 objectives from the U.S. Department of Health and Human Services identify the most significant preventable threats to health and establish national goals to reduce these threats.

“Falls can cause serious to life-threatening injuries; however, there are steps people can take at home or in a health care facility to reduce their risk of falling. We want people to be aware of these simple yet important precautions and avoid preventable injuries,” says Mark R. Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission.

The new Speak Up™ campaign offers tips and actions that will help people reduce the risk of falling, whether at home or in a medical facility. Among the topics are:

• Taking care of your health — this includes exercise to improve strength and balance, staying hydrated, having an eye exam regularly and talking to your doctor about any side effects from medications that might cause drowsiness or confusion.
• Taking extra precautions — simple actions such as turning on the lights when entering a room, keeping walkways clear, using handrails on stairs, and wearing proper shoes can make a difference.
• Making small changes to your home — using motion sensors or timers for lights, placing nightlights in bedrooms and bathrooms, removing throw rugs, and applying non-slip decals on stairs and in bathtubs to reduce the risk of falls. Home care agencies, personal care and support agencies, or community programs may be available to help you accomplish these tasks if you are older or disabled.
• Taking extra precautions in the hospital or nursing home, for example, people in health care facilities should use the call button to ask for help to get out of bed or go to the bathroom, wear non-slip socks, lower the height of the bed and bed rails, and tell the nurse or doctor if medicine is making you feel dizzy or sick.

The framework of the Speak Up™ program urges patients to:

• Speak up if you have questions or concerns, and if you don’t understand, ask again. It’s your body and you have a right to know.
• Pay attention to the care you are receiving. Make sure you’re getting the right treatments by the right health care professionals. Don’t assume anything.
• Educate yourself about your diagnosis, the medical tests you are undergoing, and your treatment plan.
• Ask a trusted family member or friend to be your advocate.
• Know what medications you take and why you take them. Medication errors are the most common health care errors.
• Use a hospital, clinic, surgery center, or other type of health care organization that has undergone a rigorous on-site evaluation against established state-of-the-art quality and safety standards, such as that provided by The Joint Commission.
• Participate in all decisions about your treatment. You are the center of the health care team.

Speak Up™ brochures also are available on preventing errors in medical care for children, finding pain relief, understanding caregivers, understanding medical tests, recovering after leaving the hospital, preventing medication mistakes, preventing infections, preparing to become a living organ donor, avoiding wrong site surgery and preventing errors in care. Brochures can be found at http://www.jointcommission.org/PatientSafety/SpeakUp/. All of the Speak Up™ brochures are available in an easy-to-read format and in Spanish.

Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission evaluates and accredits more than 17,000 health care organizations and programs in the United States, including more than 9,500 hospitals and home care organizations, and more than 6,300 other health care organizations that provide long term care, behavioral health care, laboratory and ambulatory care services. In addition, The Joint Commission also provides certification of more than 1,000 disease-specific care programs, primary stroke centers, and health care staffing services. An independent, not-for-profit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

To view this release in a media-rich format, go to: http://www.pwrnewmedia.com/2010/jointcommission_00728_Fall_Prevention/index.html

Click here to see all recent news from this company

HOUSTON, TX–(Marketwire – July 30, 2010) –  Bederra Corporation (PINKSHEETS: BEDA) management announced that the company has attained Pinksheet Current Information status on otcmarkets.com. Management had previously announced its intention to satisfy the “Alternative Reporting Standard” of public transparency in the company’s efforts to further investor relations and voluntarily make adequate and current information publicly available.

Management also noted that it remains currently in discussions with several potential acquisition candidates both in the medical area and outside this market. While the company remains dedicated to further growth in the medical services industry, management had recently announced its decision to explore diversification options in the interest of shareholders until further information regarding the overall direction of the recently passed healthcare legislation is announced. 

About Bederra Corp.
http://www.bederra.com
Bederra Corporation provides multiple modality diagnostic medical services to the greater Houston area and the world famous Texas Medical Center. The Company’s business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 30, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today reported its financial results
for the six months ended June 30, 2010 and provided a business update on
its activities.

Michele Garufi, Chairman and CEO of NicOx, declared: “This has been both an
active and a challenging first half for NicOx, as we worked with regulators
in the United States and Europe on the marketing applications for
naproxcinod. We will collaborate closely with both regulatory authorities
in the coming months. We will also focus on securing potential licensing
agreements for naproxcinod in Europe and the rest of the world, ensuring
the continued success of our existing partnerships and prioritizing our
research programs. We will continue to manage our cash resources in the
most cost-effective manner to ensure the future growth of the Company
whilst also pursuing appropriate in-licensing and M&A opportunities.”

Key events of the first six months of 2010:

– NicOx and Bausch + Lomb signed a Worldwide Licensing Agreement for the
glaucoma candidate NCX 116

– The European Medicines Agency (EMA) validated the Marketing Authorization
Application (MAA) for naproxcinod

– Joint Advisory Committee of the U.S. Food and Drug Administration (FDA)
voted that they did not have sufficient evidence to support the approval of
naproxcinod for the relief of the signs and symptoms of osteoarthritis

– Additional clinical data for naproxcinod and preclinical results for NCX
434 and NCX 1236, two of the Company’s nitric oxide (NO)-donating New
Molecular Entities, were presented at scientific and medical conferences

– NicOx and TOPIGEN Pharmaceuticals Inc. mutually terminated their
collaboration for TPI 1020 as a result of the acquisition of TOPIGEN

Post reporting period:

– On July 22, 2010, NicOx announced the receipt of a Complete Response
Letter from the U.S. Food and Drug Administration (FDA), stating that it
could not approve the New Drug Application (NDA) for naproxcinod. NicOx
plans on discussing the Complete Response Letter and potential next steps
with the FDA, as early as possible.

Eric Castaldi, Chief Financial Officer of NicOx, declared: “NicOx has a
strong cash position, with no long-term debt and cash and cash equivalents
totaling ?128.4 million at the end of June 2010. We will continue to
ensure careful conservation of our funds.”

Financial summary for the first half of 2010:

Revenues for the first half of 2010 were ?7.4 million, compared to
?1.1 million during the same period in 2009. These revenues correspond
to the initial license payment received from Bausch + Lomb in the first
quarter of the year, as per the agreement signed in March 2010.

For the first six months of 2010, operating expenses were ?36.4
million, compared to ?32.7 million for the same period in 2009. These
expenses correspond principally to personnel costs related to the
regulatory processes for naproxcinod both in the United States and in
Europe, investments in naproxcinod’s supply chain and costs related to the
anticipated cancellation of certain manufacturing and pre-commercial
activities following the decision of the FDA.

NicOx recorded a total net loss for the period of ?27.5 million for
the first six months of 2010, compared to a corresponding net loss of
?27.2 million for the same period in 2009. On June 30, 2010, NicOx had
cash and cash equivalents of ?128.4 million, compared to ?148.3
million on December 31, 2009.

Review of the first six months of 2010:

Signature of a Worldwide Licensing Agreement with Bausch + Lomb

In March 2010, NicOx and Bausch + Lomb signed a Worldwide Licensing
Agreement granting Bausch + Lomb exclusive rights to develop and
commercialize NCX 116, an NO-donating prostaglandin F2-alpha analog for the
potential treatment of glaucoma and ocular hypertension. Both companies
have already held an initial meeting to agree on the next steps for the
development of NCX 116. Under the terms of this agreement, NicOx received
an initial license payment of $10 million and stands to receive potential
milestones totaling $169.5 million, as well as tiered double-digit
royalties on the sales of NCX 116.

Regulatory status of naproxcinod in the United States

A Joint Advisory Committee of the FDA, including the Arthritis Drugs
Advisory Committee and the Drug Safety and Risk Management Advisory
Committee, voted by 16 to 1 with 1 abstention on May 12, 2010 that they did
not have sufficient evidence at that time to support the approval of
naproxcinod for the relief of the signs and symptoms of osteoarthritis.

On July 22, 2010, NicOx announced the receipt of a Complete Response Letter
from the U.S. Food and Drug Administration (FDA) related to the New Drug
Application (NDA) for naproxcinod. The FDA informed NicOx that its review
of the NDA was complete and that it did not approve the naproxcinod
application. The FDA recommended conducting one or more long-term
controlled studies to assess the cardiovascular and gastrointestinal safety
of naproxcinod. Additional studies to demonstrate a clinically meaningful
therapeutic benefit attributable to the nitric oxide donation were also
recommended. No clinical efficacy studies were requested. NicOx plans to
discuss the Complete Response Letter and potential next steps as early as
possible with the FDA.

Regulatory status of naproxcinod in Europe

In January 2010, the European Medicines Agency (EMA) validated the
Marketing Authorization Application (MAA) for naproxcinod, which was
submitted through the centralized procedure in December 2009. NicOx is
seeking approval for an indication for the relief of the signs and symptoms
of primary osteoarthritis. The Medicinal Products for Human Use (CHMP)
opinion is expected by mid-2011, the exact timing depending on the
interactions needed with the health authorities in the last phase of the
review process.

Presentation of scientific results for naproxcinod

Detailed results from the 301 study were published in the May issue of
Osteoarthritis and Cartilage. Additional clinical data for naproxcinod were
presented in May at the American Society of Hypertension Annual Scientific
Meeting and Exposition in New York and in June at the European Meeting on
Hypertension in Olso and the Annual European Congress of Rheumatology in
Rome.

Presentation of promising preclinical results in international conferences

Preclinical results obtained with two of NicOx’s NO-donating New Molecular
Entities (NMEs) were presented in congresses in the first half of 2010. In
May, preclinical findings obtained with NCX 1236, a lead compound for the
potential treatment of Neuropathic Pain, were presented at the
International Congress on Neuropathic Pain in Athens. Preclinical results
for NCX 434, a potential preclinical candidate in Diabetic Macular Edema
(DME), were presented in May at the Ocular Diseases & Drug Discovery
conference in Boston and in June at the Retina International World Congress
in Stresa.

Review of the consolidated financial results for the six months ended June
30, 2010 and 2009:

Revenues

NicOx’s revenues totaled ?7.4 million for the six months ended June
30, 2010 compared to ?1.1 million for the six months ended June 30,
2009.

This significant increase results from the recognition as revenues during
the first quarter of 2010 of ?7.4 million corresponding to the initial
license payment received from Bausch + Lomb following the signature of a
licensing agreement in March 2010 that granted Bausch + Lomb exclusive
worldwide rights to develop and commercialize NCX 116. This amount has been
immediately recognized in revenues because the Company will not have
continuing involvement in the future development of the compound which is
subject of this collaboration agreement. No revenues have been recorded in
the second quarter of 2010.

Operating expenses

For the six months ended June 30, 2010, operating expenses totaled
?36.4 million, compared to ?32.7 million for the six months ended
June 30, 2009, of which, 74% was attributable to research and development
expenses and 26% attributable to selling and administrative expenses in the
first semester of 2010, compared to 77% and 23% respectively in the first
semester of 2009.

Research and development expenses were ?26.9 million during the first
semester of 2010, compared to ?25.1 million during the first semester
of 2009 (including ?0.1 million allocated to cost of sales in 2009
corresponding to the expenses incurred by NicOx in performing research
activities under the contract signed with Pfizer). In the first semester of
2010, research and development expenses correspond principally to personnel
expenses related to the activities performed in relation with the
naproxcinod New Drug Application and Marketing Authorization Application
submitted respectively in the US and in Europe and to investment expenses
in dedicated manufacturing facilities of its active ingredient supplier DSM
in order to increase the naproxcinod supply chain capacity and flexibility.
Following the decision in July 2010 of the FDA not to approve the marketing
application for naproxcinod in the US, indemnities in an amount of
?6.9 million have been booked as research and development expenses in
the accounts as of June 30, 2010, to be paid to suppliers involved in the
manufacturing of naproxcinod for the anticipated cancellation of purchase
orders. The Company employed 79 people in research and development on June
30, 2010, compared to 93 people at the same date in 2009.

General and administrative expenses were ?3.2 million in the first
semesters of 2010 and 2009 and include personnel expenses in administrative
and financial functions, as well as the remuneration of corporate officers,
including stock option, free share and warrant attributions. Selling and
corporate development expenses totaled ?6.2 million during the first
six months ended June 30, 2010 compared to ?4.4 million during the
same period in 2009 and correspond to market research and analysis
activities for naproxcinod, as well as the business development and
communication activities of the Company. The Company employed 48 people in
its selling, general and administrative departments on June 30, 2010,
compared to 39 people on June 30, 2009.

Other income

Other income totaled ?1.6 million during the first semester of 2010
compared to ?3.1 million in the first semester of 2009. Other income
corresponds mainly to the operational subsidies from the research tax
credits in France and in Italy.

Operating result

The operating loss amounted to ?27.4 million in the six months ended
June 30, 2010, compared to ?28.5 million in the same period in 2009.

Other results

Net financial income totaled ?0.1 million during the first semester of
2010, compared to ?1.3 million during the first semester of 2009, and
represents mainly the returns on the financial investments of the Company’s
cash, cash equivalents.

The income tax expense incurred by NicOx during the first six months of
2010 relates to tax from its US and Italian subsidiaries and totaled
?0.3 million, compared to ?0.1 million during the same period in
2009.

Total net loss of the period

The total net loss for the period was ?27.5 million on June 30, 2010,
compared to ?27.2 million on June 30, 2009. Notwithstanding the strong
increase of the revenues recognized in the first six months of 2010
following the initial license payment received from Bausch + Lomb, the
total net loss on June 30, 2010 remains at the same level as last year due
to the impact of the anticipated cancellation of manufacturing and pre-
commercial activities related to naproxcinod following the decision of the
FDA not to approve the application of the product in the United States.

Consolidated statement of financial position

The indebtedness incurred by NicOx is mainly short-term operating debt. On
June 30, 2010, the Company’s current liabilities totaled ?16.6
million, including ?12.0 million in accounts payable to suppliers and
external collaborators (including ?5.9 million with respect to the
cancellation of orders of naproxcinod active drug substance), ?2.5
million in accrued compensation for employees, ?1.9 million in other
contingencies and liabilities (corresponding to the costs related to the
anticipated cancellation of certain manufacturing and pre-commercial
activities following the decision of the FDA) and ?0.2 million for
other liabilities.

The Company’s cash and cash equivalents were ?128.4 million on June
30, 2010, compared to ?148.3 million on December 31, 2009, and
?76.8 million on June 30, 2009. In late 2009, the Company completed a
two step capital increase and received a total of ?94.6 million
corresponding to the net proceeds of the following operations: ?29.4
million from a private placement of shares to institutional investors
completed on November 23, 2009, and ?65.2 million from a rights issue
completed on December 23, 2009.

NicOx will continue to pursue the European regulatory process for
naproxcinod and follow-up with the FDA after the Complete Response Letter.
NicOx will actively seek to enter into partnerships for naproxcinod. The
Company’s cash position is strong and NicOx is taking all necessary steps
to preserve it.

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements. For a discussion of
risks and uncertainties which could cause actual results, financial
condition, performance or achievements of NicOx S.A. to differ from those
contained in the forward-looking statements, please refer to the Risk
Factors (“Facteurs de Risque”) section of the Document de Reference filed
with the AMF, which is available on the AMF website (http://www.amf-
france.org) or on NicOx S.A.’s website (http://www.nicox.com).

+-------------------------+-+--------------------+-+---------+
|                         | |For the period ended| |         |
|                         | |June 30,            | |         |
+-------------------------+-+--------------------+-+---------+
|                         | |2010                | |    2009 |
+-------------------------+-+--------------------+-+---------+
|                         | |(in thousands of EUR| |         |
|                         | |except for per share| |         |
|                         | |data)               | |         |
+-------------------------+-+--------------------+-+---------+
|Revenues                 | |7,423               | |   1,119 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Cost of sales            | |-                   | |    (75) |
|                         | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Research and development | |(26,924)            | |(25,031) |
|expenses                 | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Administrative expenses  | |(3,214)             | | (3,234) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Selling expenses         | |(6,241)             | | (4,403) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Other income             | |1,600               | |   3,130 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Operating loss           | |(27,356)            | |(28,494) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Finance income           | |183                 | |   1 388 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Finance expense          | |(70)                | |    (54) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Loss before income tax   | |(27,243)            | |(27,160) |
|                         | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Income tax expense       | |(257)               | |    (77) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Net loss of the          | |(27,500)            | |(27,237) |
|period                   | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Exchange differences on  | |(38)                | |     (1) |
|translation of foreign   | |                    | |         |
|operations               | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Other comprehensive      | |(38)                | |     (1) |
|income (loss) for the    | |                    | |         |
|period, net of tax       | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Total comprehensive      | |(27,538)            | |(27,238) |
|income (loss) for the    | |                    | |         |
|period, net of tax       | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Attributable to:         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|- Equity holders of the  | |(27,538)            | |(27,238) |
|parent                   | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|- Non-controlling        | |-                   | |       - |
|interests                | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Basic and diluted loss   | |(0.38)              | |  (0.57) |
|per share attributable to| |                    | |         |
|equity holders of the    | |                    | |         |
|parent                   | |                    | |         |
+-------------------------+-+--------------------+-+---------+

+----------------------+--------------------+-+------------------+--------+
|                      |   June 30, 2010    | |December 31, 2009 |        |
+----------------------+--------------------+-+------------------+--------+
|                      |(in thousands       | |                  |        |
|                      | of EUR)            | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|ASSETS                |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-current assets    |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Property, plant &     |              2,782 | |                  |  2,772 |
|equipment             |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Intangible assets     |                794 | |                  |    797 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Government subsidies  |                936 | |                  |    477 |
|receivable            |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other financial assets|                267 | |                  |    238 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Deferred income tax   |                  - | |                  |    156 |
|assets                |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total non-current     |              4,779 | |                  |  4,440 |
|assets                |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current assets        |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Government subsidies  |              3,263 | |                  |  2,597 |
|receivable            |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other current assets  |                988 | |                  |  1,329 |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Prepaid expenses      |              1,213 | |                  |    784 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Cash and cash         |            128,448 | |                  |148,275 |
|equivalents           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total current assets  |            133,912 | |                  |152,985 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|TOTAL ASSETS          |            138,691 | |                  |157,425 |
+----------------------+--------------------+-+------------------+--------+
|EQUITY AND LIABILITIES|                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Common shares         |             14,505 | |                  | 14,434 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other reserves        |            103,046 | |                  |128,444 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-controlling       |                  - | |                  |      - |
|interests             |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total Equity          |            117,551 | |                  |142,878 |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-current           |                    | |                  |        |
|liabilities           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other contingencies   |              4,369 | |                  |  4,069 |
|and liabilities       |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Deferred income tax   |                 98 | |                  |     91 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Finance lease         |                 44 | |                  |      6 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total non-current     |              4,511 | |                  |  4,166 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current liabilities   |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other contingencies   |              1,890 | |                  |      - |
|and liabilities       |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Finance lease         |                 18 | |                  |      7 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Trade payables        |             12,034 | |                  |  6,136 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current income tax    |                  - | |                  |     19 |
|payable               |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Social security and   |              2,504 | |                  |  3,909 |
|other taxes           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other liabilities     |                183 | |                  |    310 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total current         |             16,629 | |                  | 10,381 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|TOTAL EQUITY AND      |            138,691 | |                  |157,425 |
|LIABILITIES           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|NicOx S.A.,           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Les Taissounières-Bât |                    | |                  |        |
|HB4 - 1681 route des  |                    | |                  |        |
|Dolines - BP313, 06906|                    | |                  |        |
|Sophia Antipolis cedex|                    | |                  |        |
|France.               |                    | |                  |        |
|Tel.                  |                    | |                  |        |
|+33 (0)4 9724 53 00   |                    | |                  |        |
|Fax                   |                    | |                  |        |
|+33 (0)497 24 53 99   |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
+----------------------+--------------------+-+------------------+--------+

This information is provided by HUGIN

SAN DIEGO, CA–(Marketwire – July 29, 2010) –  Medistem Inc. (PINKSHEETS: MEDS) announced today publication of a peer reviewed paper identifying a molecule found on the company’s lead product, the universal donor Endometrial Regenerative Cell (ERC), as a key component of cellular escape from immune attack. The study, titled “Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated with low expression of alpha-Gal and high production of clusterin and CD59,” was published in the journal Xenotransplantation as a collaboration between Medistem and the Institute of Organ Transplantation, Tongji Hospital, in Wuhan, China.

The study found that CD59, a molecule made by ERC, plays an important role in protecting cells from immune rejection when placed in contact with immune components from another species. The ERC is a mesenchymal-like stem cell that Medistem discovered in 2007 capable of generating heart, lung, brain, muscle, blood vessel, pancreas, liver, fat and bone tissue. The original description of this cell, which won the “Publication of the Year Award” may be found at http://www.translational-medicine.com/content/pdf/1479-5876-5-57.pdf.

“One of the fundamental aspects of Medistem’s lead product, the Endometrial Regenerative Cell (ERC), is its ability to function without the need for tissue matching. In other words, the ERC stem cells act as universal donors. We have previously published that human ERC are effective in treating mice having a condition that resembles critical limb ischemia (see paper http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf). We now believe that expression of the molecule CD59 on ERC may be one of the mechanisms by which these human cells can be used not only as a universal donor for humans, but also for the treatment of numerous diseases across a variety of animal species,” said Thomas Ichim, CEO of Medistem.

Medistem has filed an IND with the FDA for treatment of critical limb ischemia (severe obstruction of the arteries that leads to decreased blood flow to the extremities) with ERC. Currently the company is in the process of completing additional experiments requested by the FDA before clinical trials can commence. Through physician-initiated compassionate use mechanisms Medistem has already published on human use of ERC in treatment of heart failure, Duchenne Muscular Dystrophy, and multiple sclerosis. A recent peer-reviewed paper describing ERC in treatment of heart failure may be found at http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

MADISON, WI–(Marketwire – July 29, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), producer of the Hi*Art® treatment system and other products for
advanced radiation therapy, today released financial results for the second
quarter ended June 30, 2010.

Second Quarter Results

Second quarter 2010 revenue was $47.6 million, an increase of 16% from
$41.1 million in the second quarter of 2009. Revenue from product sales
was $34.2 million in the second quarter of 2010, up 12% compared to the
same quarter last year, and revenue from service and other was $13.4
million in the second quarter of 2010, up 27% compared to the same quarter
last year. The company reported a second quarter 2010 loss from operations
of $8.4 million, a 14% decrease from the $9.7 million loss from operations
for the same period last year.

The company incurred a net loss attributable to shareholders of $6.9
million, or $0.13 per share, for the second quarter of 2010, compared to a
net loss of $7.1 million, or $0.14 per share, for the second quarter of
2009.

As of June 30, 2010, the company had $145.7 million of cash, cash
equivalents and short-term investments, representing a $3.0 million
decrease from March 31, 2010, and minimal debt. During the quarter, there
were no borrowings against the company’s credit facility.

As of June 30, 2010, the company had a revenue backlog of $139.2 million, a
4% increase from the $134.2 million backlog as of March 31, 2010. The
backlog includes $42.5 million of equipment orders received during the
second quarter of 2010. One order was removed from backlog during the
second quarter due to uncertainty surrounding the project schedule.
Backlog includes only firm orders that the company believes are likely to
ship within the next two years. Backlog does not include any revenue from
service contracts, which represents a growing portion of the company’s
overall revenue.

“Our second quarter financial results were in line with our internal
expectations and represent a solid improvement over the same period last
year,” said Fred Robertson, TomoTherapy’s CEO. “In addition, we are
pleased with the 13% increase in revenue from the first quarter of 2010 and
the $5.0 million net increase to our backlog since March 31, 2010.
Specifically, we realized a rise in new orders, which we believe reflects
the strength of our new product offerings as well as enhanced global sales
and marketing efforts. On the service side, revenue increased
significantly compared to the same period last year, due to continued
growth in the number of service contracts, and we again achieved strong
customer service rankings. We continue to take steps to enhance our
financial performance and drive toward profitability while still investing
in key product development initiatives. Importantly, our capital position
remained strong in the quarter despite the continuing challenges in the
global economy.”

Six-Month Results

For the six months ended June 30, 2010, revenue was $89.7 million, a 25%
increase from $71.7 million for the six months ended June 30, 2009.
Revenue from product sales was $63.5 million in the first half of 2010, up
23% compared to the first half of 2009, and revenue from service and other
was $26.2 million in the first half of 2010, up 31% compared to the first
half of 2009.

The company reported a year-to-date 2010 loss from operations of $14.4
million, a 39% decrease from the loss from operations of $23.7 million
during the first six months of 2009. The company incurred a net loss
attributable to shareholders of $11.6 million, or $0.22 per share, for the
six months ended June 30, 2010, compared to a net loss attributable to
shareholders of $20.1 million, or $0.40 per share, for the same period last
year.

During the first half of 2010, the company’s cash, cash equivalents and
short-term investments decreased by $8.7 million. The company’s backlog
increased by $3.4 million during the first half of 2010, from $135.8 as of
December 31, 2009 to $139.2 million as of June 30, 2010.

Outlook

The company reaffirms its revenue and earnings guidance for full-year 2010.
Management still expects 2010 revenue to be comparable to 2009 revenue of
$160 million to $180 million, with a net loss attributable to shareholders
in the range of $0.65 to $0.85 per share. Consistent with prior years,
management is not providing specific quarterly guidance. However, similar
to 2009, management anticipates that the timing of expected customer
deliveries will result in 2010 second half revenues being heavily weighted
toward the fourth quarter.

Robertson concluded, “Given our second quarter performance and expectations
for the balance of the year, we remain on track to deliver results in line
with our previously announced guidance. While there is still uncertainty
with respect to macro conditions, particularly in Europe, we are encouraged
by recent performance in North America and Asia. We also continue to make
good progress on several key initiatives, including diversifying our
product line-up and expanding our business both in North America and other
global markets. With significant interest in our TomoDirect™ and
TomoHD™ offerings, entry into new markets, and greater access to many
hospitals through new strategic Group Purchasing Organization agreements,
we believe TomoTherapy is well positioned to capitalize on the substantial
opportunity in the growing global radiation therapy market.”

Investor Conference Call

TomoTherapy will conduct a conference call regarding its second quarter
2010 results at 5:00 p.m. EDT today, July 29, 2010 (4:00 p.m. CDT). To
hear a live Webcast or replay of the call, visit the Investor Relations page at TomoTherapy.com, where it will
be archived for two weeks. To access the call via telephone, dial
1-800-260-8140 from inside the United States or
1-617-614-3672 from outside the United States, and enter pass code
35309628. The replay can be accessed by dialing 1-888-286-8010 from inside
the United States or 1-617-801-6888 from outside the United States and
entering pass code 64325104. The telephone replay will be available
through 11:59 p.m. CDT on August 5, 2010.

About TomoTherapy Incorporated

TomoTherapy Incorporated develops, markets and sells advanced radiation
therapy solutions that can be used to efficiently treat a wide variety of
cancers, from the most common to the most complex. The ring gantry-based
TomoTherapy® platform combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with speed
and precision while reducing radiation exposure to surrounding healthy
tissue. TomoTherapy’s suite of solutions includes its flagship Hi*Art®
treatment system, which has been used to deliver more than three million
CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment
fractions; the TomoHD™ treatment system, designed to enable cancer centers
to treat a broader patient population with a single device; and the
TomoMobile™ relocatable radiation therapy solution, designed to improve
access and availability of state-of-the-art cancer care. TomoTherapy’s
stock is traded on the NASDAQ Global Select Market under the symbol “TOMO.”
To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements
concerning market acceptance of the company’s technology; growth drivers;
the company’s orders, revenue, backlog or earnings growth; future financial
results and any statements using the terms “should,” “believe,” “outlook,”
“expect,” “anticipate” or similar statements are forward-looking statements
that involve risks and uncertainties that could cause the company’s actual
results to differ materially from those anticipated. Such risks and
uncertainties include: demand for the company’s products; impact of sales
cycles and competitive products and pricing; the effect of economic
conditions and currency exchange rates; the company’s ability to develop
and commercialize new products; its reliance on sole or limited-source
suppliers; its ability to increase gross margins; the company’s ability to
meet U.S. Food and Drug Administration (FDA) and other regulatory agency
product clearance and compliance requirements; the possibility that
material product liability claims could harm future revenue or require the
company to pay uninsured claims; the company’s ability to protect its
intellectual property; the impact of managed care initiatives, other health
care reforms and/or third-party reimbursement levels for cancer care;
potential loss of key distributors or key personnel; risk of interruptions
to the company’s operations due to terrorism, disease or other events
beyond the company’s control; and the other risks listed from time to time
in the company’s filings with the U.S. Securities and Exchange Commission,
which by this reference are incorporated herein. TomoTherapy assumes no
obligation to update or revise the forward-looking statements in this
release because of new information, future events or otherwise.

                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per share data)
                                (unaudited)



                                 Three Months Ended     Six Months Ended
                                      June 30,              June 30,
                                --------------------  --------------------
                                  2010       2009       2010       2009
                                ---------  ---------  ---------  ---------

Revenue:
 Product                        $  34,242  $  30,552  $  63,471  $  51,685
 Service and other                 13,388     10,528     26,239     20,018
                                ---------  ---------  ---------  ---------
  Total revenue                    47,630     41,080     89,710     71,703
                                ---------  ---------  ---------  ---------
Cost of revenue:
 Product                           17,354     14,253     30,139     25,998
 Service and other                 17,818     18,312     34,509     34,651
                                ---------  ---------  ---------  ---------
  Total cost of revenue            35,172     32,565     64,648     60,649
                                ---------  ---------  ---------  ---------
   Gross profit                    12,458      8,515     25,062     11,054
                                ---------  ---------  ---------  ---------
Operating expenses:
  Research and development          8,960      7,020     16,500     12,869
  Selling, general and
   administrative                  11,910     11,224     22,944     21,876
                                ---------  ---------  ---------  ---------
   Total operating expenses        20,870     18,244     39,444     34,745
                                ---------  ---------  ---------  ---------
Loss from operations               (8,412)    (9,729)   (14,382)   (23,691)
Other income (expense):
  Interest income                     416        695        947      1,392
  Interest expense                    (12)       (15)       (23)       (29)
  Other expense, net                 (578)      (107)    (1,026)      (363)
                                ---------  ---------  ---------  ---------
   Total other income (expense)      (174)       573       (102)     1,000
                                ---------  ---------  ---------  ---------
Loss before income tax and
 noncontrolling interests          (8,586)    (9,156)   (14,484)   (22,691)
  Income tax expense (benefit)         10       (318)       (34)      (418)
                                ---------  ---------  ---------  ---------
Net loss                           (8,596)    (8,838)   (14,450)   (22,273)
  Noncontrolling interests          1,673      1,715      2,849      2,151
                                ---------  ---------  ---------  ---------
Net loss attributable to
 shareholders                   $  (6,923) $  (7,123) $ (11,601) $ (20,122)
                                =========  =========  =========  =========

Weighted-average common shares
 outstanding -
 basic and diluted                 51,713     50,592     51,640     50,592
                                =========  =========  =========  =========

Loss per common share - basic
 and diluted                    $   (0.13) $   (0.14) $   (0.22) $   (0.40)
                                =========  =========  =========  =========





                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

                  CONDENSED CONSOLIDATED BALANCE SHEETS
                              (In thousands)
                                (unaudited)


                                                    June 30,   December 31,
                                                      2010         2009
                                                  ------------ ------------

                                  ASSETS
Cash and cash equivalents                         $     99,240 $     76,108
Short-term investments                                  46,434       78,225
Receivables, net                                        32,915       33,559
Inventories, net                                        53,204       47,669
Prepaid expenses and other current assets                5,507        3,633
                                                  ------------ ------------
 Total current assets                                  237,300      239,194
Property and equipment, net                             18,198       18,628
Other non-current assets, net                           10,588       12,429
                                                  ------------ ------------
 TOTAL ASSETS                                     $    266,086 $    270,251
                                                  ============ ============

                           LIABILITIES AND EQUITY
Accounts payable                                  $     11,896 $      6,269
Accrued expenses                                        20,273       19,588
Accrued warranty                                         3,776        4,173
Deferred revenue                                        31,506       34,145
Customer deposits                                       11,145       13,266
                                                  ------------ ------------
 Total current liabilities                              78,596       77,441
Other non-current liabilities                            4,404        5,475
                                                  ------------ ------------
 TOTAL LIABILITIES                                      83,000       82,916

Total shareholders' equity                             175,498      183,424
Noncontrolling interests                                 7,588        3,911
                                                  ------------ ------------
 TOTAL EQUITY                                          183,086      187,335

                                                  ------------ ------------
 TOTAL LIABILITIES AND EQUITY                     $    266,086 $    270,251
                                                  ============ ============

WAYNE, PA–(Marketwire – July 29, 2010) –  Clinical and Laboratory Standards Institute (CLSI) unveiled the release of StatisPro^™, its new method evaluation software package for the evaluation, verification, and validation of performance characteristics of laboratory test methods at the AACC/ASCLS Annual Meeting this week.

StatisPro software delivers a feature-rich tool designed to perform the statistical analysis necessary to meet regulatory and accreditation requirements. Hospitals, physician office laboratories, reference laboratories, and customer support departments of in vitro diagnostic manufacturers can benefit from using this new method evaluation software.

David Grenache, PhD, DABCC, FACB, Associate Professor, Department of Pathology, University of Utah, ARUP Laboratories, and beta-tester for StatisPro, says, “The benefits of StatisPro are its ease-of-use and intuitive interface. When validating a new method, replacing equipment, or preparing for accreditation or regulatory inspections, StatisPro makes advanced statistical analysis easier regardless of the size of the laboratory using it.”

Developed in conjunction with Analyse-it^®, StatisPro can produce reports on analytical accuracy, precision, linearity, limit of detection and quantitation, and reference intervals and is entirely based on the most up-to-date CLSI guidelines.

With StatisPro, laboratories can:

• Verify comparability of new methods and systems.
• Ensure comparable results across measuring systems.
• Establish reference intervals or transfer intervals between methods and laboratories.

James Huntington, Co-founder, Analyse-it^®, describes the importance of evaluating and verifying method performance, saying, “Laboratories must ensure method performance is as expected to meet regulatory or accreditation requirements. As the statistics necessary to determine method performance become more complex, software such as StatisPro is essential to ensure accurate, correct, determination of method performance.”

CLSI partnered with Analyse-it because of its excellent reputation and proven experience in creating statistically based software, as well as its similar culture and values to CLSI, explains Glen Fine, MS, MBA, CAE, CLSI Executive Vice President. “Since StatisPro is based on CLSI’s world-renowned best practices, it will inspire user confidence. This is the only software package available that streamlines implementation of CLSI’s latest method evaluation guidelines. StatisPro allows staff of laboratories of any size to produce advanced statistical calculations and display reports quickly and accurately in order to ensure the highest quality patient care,” says Fine. 

StatisPro is available directly from CLSI. For more information, please visit www.StatisPro.org or call 877.477.1888.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information visit the CLSI website at www.clsi.org or call 610.688.0100.

Analyse-it Software, Ltd. formed in 1997 to develop statistical analysis and charting software for Microsoft^® Excel^™, and built its flagship product, Analyse-it, through work with some of the world’s largest in vitro diagnostic companies. Now with more than 20,000 customers, Analyse-it is highly respected in the scientific and research community, and is used and cited in thousands of peer-reviewed published papers. For additional information, visit the Analyse-it website at www.analyse-it.com.

Click here to see all recent news from this company

KELLER, TX–(Marketwire – July 29, 2010) – In less time than it takes for a single lunch hour, employees can learn, for free, how to save a life through Cardiopulmonary Resuscitation (CPR). This because Dallas-based non-profit Mission CPR (www.MissionCPR.org) has launched its “Spend 45 Minutes, Save a Life” initiative offering workplace CPR awareness and basic skills training to area businesses and organizations completely free of charge. Mission CPR has launched this program as part of the American Heart Association’s overriding “CPR Anytime” campaign created to increase the incidence of bystander CPR by making training more accessible.

“A full 93.6 percent of sudden cardiac arrest victims die simply because the vast majority of those witnessing the arrest do not know how to perform CPR and are reluctant to even try,” says Jeff D. Hill, CEO of Mission CPR, whose own life was saved by CPR at age 3 and who has since saved a life using CPR through his work as an EMT. “Our organization aims to not only raise awareness about the vital importance of bystander CPR, but also actually save lives by providing local groups with basic, easily absorbed training in a convenient on-site workplace setting — at no cost to the employee, group member or organization.” 

“The session lasts only 45 minutes and very little time is needed to organize the presentation,” Hill underscores. “This program is an invaluable employee benefit that has nothing but upside for all involved — the company, employee, their families and the Dallas/Fort Worth community at large.”

At the age of 3, Hill’s own life was saved by bystander CPR. Left briefly unattended, he fell in a pool and drowned. Hill had no heartbeat and had stopped breathing completely. A visiting relative heard his mother screaming once she pulled Hill from the pool, and he jumped in to try to help. This relative had received CPR training years before and was unsure if he was “doing it right,” but he TRIED his best, revived Hill’s heartbeat, and kept him alive long enough until the EMS arrived to take over. This experience exemplifies why even the most basic understanding of CPR is important and how those skills can prove critical in an emergency situation.

Hill notes, “The reality is many people in distress that need CPR do not get the help because bystanders are not trained or are afraid to try. Indeed, in my prior work as a firefighter and EMT, most bystanders waited until we arrived to attempt CPR and, most often, it was too late. Even the most basic skills training can give someone the knowledge and confidence needed to attempt CPR until medical professionals arrive, and can mean the difference between life and death.”

In addition to its free “Spend 45 Minutes, Save a Life” training program, Mission CPR also offers interested and key employees full certification-based CPR and First Aid training at a reduced cost, with proceeds used to purchase additional American Heart Association CPR training kits to support and prolong the organization’s free training efforts. Mission CPR sessions are available for company meetings and conferences, “lunch and learns,” health fairs, benefits enrollment periods or any other time that best suits the business or organization. 

Interested parties may visit www.MissionCPR.org to learn more about Mission CPR’s free and reduced-fee certification programs. More information about the American Heart Association’s “CPR Anytime” campaign may be accessed online at http://www.trihealth.com/aus/srv/CPR_Anytime.aspx.

About Mission CPR
Based in Keller, Texas, Mission CPR is a non-profit organization dedicated to raising awareness about the vital importance of bystander CPR in both a local and nationwide effort to save lives. The organization provides free CPR awareness presentations and basic skills training, and reduced-cost CPR and First Aid certifications, to businesses and organizations of all types throughout the Dallas/Fort Worth region. Mission CPR is spearheaded by CPR recipient and survivor Jeff D. Hill who himself, as a former EMT, has saved the life of another using CPR. Contact Mission CPR at 817-509-0004 or [email protected], or learn more about the organization online at www.MissionCPR.org.

Click here to see all recent news from this company

HALIBURTON, ON–(Marketwire – July 29, 2010) – Patient News, a leading dental marketing company in the US and Canada, was recognized for its outstanding newsletter design and layout in the 22nd Annual Awards for Publication Excellence Competition (APEX). Judged by a panel of experienced writers and editors, the APEX 2010 awards are based on excellence in graphic design, editorial content, and the ability to achieve overall communications excellence. Despite an exceptionally intense competition with more than 3,700 entries, Patient News received an Award for Publication Excellency by Apex 2010 for Dr. Randy G. Fussell’s Fall 2009 dental marketing newsletter “Smile! Pass It on!”

“At Patient News we take great pride in our highly skilled editorial, design, and production teams who work together to create engaging, innovative, and personable patient marketing and potential patient marketing materials that speak directly to our clients’ targeted audience,” said Karen Galley, President of Patient News. “As the industry leader, our customized marketing methods are proven, reliable, professional, and diverse.”

Patient News offers a variety of innovative dental marketing products including dental email newsletters, patient newsletters, direct mail newsletters, dental postcards, patient referral cards and patient satisfaction surveys. All products are tailored to help achieve the specific goals of each client. With nearly 20 years of business and over 100 million newsletters and postcards later, Patient News provides health care specialists with measurably effective practice marketing. In addition to the APEX 2010 Award for Publication Excellency, Patient News has received a number of other awards, including Entrepreneur of the Year, Large Business of the Year, and the American Graphic Design Award.

Patient News has been producing dental marketing materials for almost 20 years in North America and the UK. For additional information on dental marketing from Patient News, call 800.667.0268 or visit www.patientnews.com. To read more on this topic, visit: http://www.patientnews.com/pressreleases/dental-marketing-excellency-award.html.

About Patient News:
 Patient News is North America’s most comprehensive and innovative dental marketing solutions provider. Founded in Canada in 1992, the company produces award-winning healthcare and dental marketing products in Canada, the United States, and the United Kingdom. The company has been named a Top 100 employer for four consecutive years, and has officially added environmental sustainability to its core values within the company vision.
Contact:

Click here to see all recent news from this company

WAYNE, PA–(Marketwire – July 29, 2010) –  Kenexa (NASDAQ: KNXA), a global provider of business solutions for human resources, today announced that a trio of executives from global and regional healthcare-related companies will share their unique perspectives on talent acquisition and employee engagement during the upcoming 2010 Kenexa World Conference. Gina Nardone, Manager of Talent Acquisition for Baxter Healthcare; Kristy Rigot, System Director of Human Resources for Lee Memorial Health System; and Cathy Fraser, Senior Vice President of Human Resources for Tenet Healthcare Corporation will add their voices to the conference, sharing best practices that are changing the face of HR.

In a session titled “The Effective Great Unknown: Global Expansion in a Decentralized Talent Acquisition Organization,” Nardone will focus on Baxter’s global implementation of Kenexa Recruiter® BrassRing, highlighting the company’s specific challenges, including the initial absence of a strong global talent acquisition presence across the organization. Nardone will explain how Baxter has achieved 85% implementation across the organization, with a goal of 100% by the end of 2011. Recommendations on conducting Delta Workshops, language implementation, dealing with HR turnover, working with limited budgets and post-implementation involvement also will be discussed.

Improving recruitment productivity is not about doing things faster and harder. It is about streamlining work process, standardizing, modifying behaviors, optimizing technology and staying focused on key recruitment workforce metrics. During her presentation of “Soar with the Eagles: Improving Recruitment Productivity,” Rigot will provide an overview of Lee Memorial Health System’s focus on performance improvement strategies and goals based on continuous analysis of candidate pipeline, workflow and performance metrics.

In a presentation titled “Achieving Impact by ‘Under-thinking’ Traditional HR,” Fraser will share how textbook HR does not always make sense, describing different thinking in the traditional towers of talent management, performance management, employee engagement, and anti-unionization, tuned at achieving impact. During this intriguing session, Fraser will highlight the importance of context and organizational readiness, with the backdrop of Tenet Healthcare’s business turnaround.

The fifth annual Kenexa World Conference promises to transform HR through outliers, helping organizations move beyond potential to drive business performance. To reveal true human potential to improve business results, companies must identify and nurture high performers and create the right environment for them to thrive. Attendees of the conference will come to understand how the right individuals in the right environment lead to ultimate success.

Happening Tuesday, September 21 through Thursday, September 23, 2010, in Philadelphia, Pa., the Kenexa World Conference will give companies the information they need to transform HR and move from potential to performance. The 2010 Kenexa World Conference will be held at The Sheraton Society Hill Hotel, One Dock Street, Philadelphia, Pa. For more information or to register, visit www.kenexa.com.

About Kenexa
Kenexa® provides business solutions for human resources. We help global organizations multiply business success by identifying the best individuals for every job and fostering optimal work environments for every organization. For more than 20 years, Kenexa has studied human behavior and team dynamics in the workplace, and has developed the software solutions, business processes and expert consulting that help organizations impact positive business outcomes through HR. Kenexa is the only company that offers a comprehensive suite of unified products and services that support the entire employee lifecycle from pre-hire to exit. Additional information about Kenexa and its global products and services can be accessed at www.kenexa.com.

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – July 29, 2010) –  US-based Radient Pharmaceuticals Corporation (NYSE Amex: RPC) announced today Perceptive Imagineering has launched a Spanish language website (www.perceptive-imagineering.com/onko-sure) adapted for the Latin American culture in support of the product commercialization for RPC’s proprietary, USFDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test. 

As RPC’s distribution partner for Central America, South America, Mexico and the Caribbean, Perceptive Imagineering is responsible for commercialization efforts, including product registration, marketing, sales and support for the licensing and distribution of Onko?Sure in these regions. The newly launched site is a companion to RPC’s corporate websites: Radient-Pharma.com and Onko-Sure, and delivers detailed information on Radient Pharmaceuticals, Onko-Sure and Onko-Sure product sales and distribution in Latin American and surrounding regions. This website also includes a valuable FAQ section with answers to the most commonly asked questions about Onko-Sure, scientific literature regarding the test, basic information about cancer and cancer testing in Latin America, RPC’s CLIA laboratory testing resources and general information on cancer screening, testing and treatment.

According to Douglas MacLallan, Chairman and CEO of Radient Pharmaceuticals, “The launch of this new site supports our commercialization efforts in Latin America and serves as a critical communication tool in this geographical region. The site is an invaluable resource to educate our key Latin American audiences, which include cancer patients, the medical and healthcare community at large, existing and prospective investors, partners and suppliers on the Company and Onko-Sure and Onko-Sure’s merits as a non-invasive, simple blood test for cancer screening and testing.”

Perceptive specializes in assisting US medical companies in bringing their products into Latin America. Perceptive Imagineering, LLC is led Dr. Nancy Alvarez, and, under her leadership, her company is well?suited to lead the licensing, distribution and commercialization efforts for RPC’s Onko?Sure cancer test in this market.

Onko-Sure IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.

About Radient Pharma:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic Cancer tests. The Company’s focus is on the discovery, development & commercialization of unique high?value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Our Onko?Sure™ IVD cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. For additional information on RPC and its portfolio of cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

UTICA, NY–(Marketwire – July 29, 2010) – CONMED Corporation (NASDAQ: CNMD) today announced
financial results for the second quarter of 2010.

Sales for the second quarter ended June 30, 2010 were $181.1 million
compared to $164.6 million in the same quarter of 2009, an increase of 10
percent. GAAP diluted earnings per share were $0.25 compared to $0.05 in
the second quarter of 2009. Non-GAAP diluted earnings per share equaled
$0.32 compared to non-GAAP diluted earnings per share of $0.17 in the 2009
second quarter. As discussed below under “Use of Non-GAAP Financial
Measures,” the Company presents various non-GAAP financial measures in this
release. Investors should consider non-GAAP measures in addition to, and
not as a substitute for, or superior to, financial performance measures
prepared in accordance with GAAP. Please refer to the attached
reconciliation between GAAP and non-GAAP financial measures.

For the six months ended June 30, 2010, sales were $357.5 million compared
to $328.6 million in the first six months of 2009, an increase of 8.8
percent. GAAP diluted earnings per share were $0.50 for year-to-date June
2010 compared to $0.20 in the same period of 2009. Non-GAAP diluted
earnings per share were $0.60 for the 2010 six-month period compared to
$0.36 in 2009.

“The results of the 2010 second quarter improved upon the positive
performance of the first quarter of the year,” commented Mr. Joseph J.
Corasanti, President and Chief Executive Officer. “Single-use product
sales, once again, produced solid year-over-year growth, while capital
product sales experienced significant growth, 18.9 percent in constant
currency, over the second quarter of last year. This overall sales growth,
together with the continued realization of cost efficiencies from ongoing
restructuring initiatives, resulted in substantially improved earnings
compared to a year ago.”

International sales in the second quarter of 2010 were $87.9 million,
representing 48.5% of total sales, and $172.9 million for the six-months
ended June 30, 2010. Favorable currency exchange rates in 2010 led to an
increase in sales of $3.2 million compared to exchange rates in the second
quarter of 2009, and $11.1 million for the six-month period of 2010.

Cash provided from operating activities outpaced net income in the second
quarter of 2010 and amounted to $18.5 million, or 10.2 percent of sales.
The cash was used to repay debt and repurchase the Company’s common stock,
as further explained below.

Outlook

Mr. Corasanti added, “We believe that the results of the second quarter of
2010, as well as what we are hearing from our sales force, indicates that
our customers are returning to historical purchasing trends as compared to
the instability experienced in 2009 due to the global economic crisis.
Consequently, we expect that sales in the third quarter of 2010 will
experience a normal seasonal sequential reduction from the second quarter
2010 and that the sales of the fourth quarter of 2010 should be the
strongest of the year, as we’ve seen historically. For the third quarter
of 2010, we expect sales to approximate $174 – $179 million with non-GAAP
diluted earnings per share of $0.25 – $0.30. For the full year of 2010, we
are reiterating our previously communicated guidance, with sales estimated
to be $715 – $725 million and non-GAAP diluted earnings per share of $1.20
– $1.30.”

The sales and earnings forecasts have been developed using July 2010
currency exchange rates and take into account the currency hedges entered
into by the Company. We estimate that 80% of the currency exposure is
hedged for the third quarter 2010 and 60% hedged for the fourth quarter.

The non-GAAP estimates for the year and the third quarter exclude the
additional non-cash interest expense required by recently issued Financial
Accounting Standards Board (“FASB”) guidance, the loss on repurchase and
retirement of our Convertible Notes and all of the manufacturing and
administrative restructuring costs expected to be incurred in 2010.

Restructuring costs

During the second quarter of 2010, the Company consolidated various
administrative functions in its CONMED Linvatec division and continued the
transfer of additional product lines to its Mexican manufacturing facility.
Expenses associated with these activities, including severance and
relocation costs, amounted to $2.0 million in the second quarter of 2010
and $2.5 million for the six months ended June 30, 2010. These charges are
included in the GAAP earnings per share set forth above and are excluded
from the non-GAAP results. CONMED expects additional restructuring charges
for the remainder of 2010 to approximate $1.5 million; these costs are
excluded from non-GAAP earnings estimates.

Stock and bond repurchase

During the second quarter of 2010, utilizing the Company’s current cash
flow, CONMED repurchased approximately 475,000 shares of its common stock,
amounting to $9.5 million, and also repurchased and retired $3.0 million
face value of its 2.5 percent Convertible Notes at a discount of
approximately 3 percent. The remaining availability under the Board of
Directors’ authorization for stock repurchases currently amounts to $37.3
million, and additional shares under this authority may be repurchased
using the Company’s cash flow.

Convertible note interest expense

As previously disclosed, and in accordance with guidance recently issued by
the FASB, the Company is now required to record non-cash interest expense
related to its convertible notes to bring the effective interest rate to a
level approximating that of a non-convertible note of similar size and
tenor. In the second quarters of 2010 and 2009, CONMED recorded additional
non-cash pre-tax interest charges of $1.1 million and $1.0 million,
respectively. For the first six-months of 2010 and 2009, such charges
amounted to $2.1 million in each period. These charges are included in the
GAAP earnings per share set forth above, and excluded from the non-GAAP
amounts.

Accounts receivable financing — change in accounting

As previously disclosed, recently issued FASB guidance requires that
CONMED’s accounting for its accounts receivable financing facility be
changed as of January 1, 2010. Previously, the sale of accounts receivable
to a bank removed the sold receivables from the Company’s balance sheet.
In 2010 and future years, the new guidance requires that the receivables
remain on CONMED’s balance sheet and that the financing transaction be
recorded as a liability. Usage of the facility amounted to $31.0 million
at June 30, 2010. Accordingly, as of June 30, 2010, compared to the
previous off-balance sheet accounting, accounts receivable is $31.0 million
greater because the full amount of receivables remains on the balance
sheet, and the current portion of long-term debt includes the $31.0 million
usage of the receivable facility. Further, cash provided by operating
activities on the June 30, 2010 statement of cash flows is reduced by $29.0
million as a result of the change in accounting. See the attached
reconciliation of cash flow provided by operating activities. This
accounting change had no effect on the consolidated statement of income.

Use of Non-GAAP Financial Measures

Management has disclosed financial measurements in this press announcement
that present financial information that is not in accordance with Generally
Accepted Accounting Principles (“GAAP”). These measurements are not a
substitute for GAAP measurements, although Company management uses these
measurements as aids in monitoring the Company’s on-going financial
performance from quarter-to-quarter and year-to-year on a regular basis,
and for benchmarking against other medical technology companies. Non-GAAP
net income and non-GAAP earnings per share measure the income of the
Company excluding unusual credits or charges that are considered by
management to be outside of the normal on-going operations of the Company.
Management uses and presents non-GAAP net income and non-GAAP earnings per
share because management believes that in order to properly understand the
Company’s short and long-term financial trends, the impact of unusual items
should be eliminated from on-going operating activities. These adjustments
for unusual items are derived from facts and circumstances that vary in
frequency and impact on the Company’s results of operations. Management
uses non-GAAP net income and non-GAAP earnings per share to forecast and
evaluate the operational performance of the Company as well as to compare
results of current periods to prior periods on a consistent basis.
Non-GAAP financial measures used by the Company may be calculated
differently from, and therefore may not be comparable to, similarly titled
measures used by other companies. Investors should consider non-GAAP
measures in addition to, and not as a substitute for, or superior to,
financial performance measures prepared in accordance with GAAP.

Conference call

The Company will webcast its second quarter 2010 conference call live over
the Internet at 10:00 a.m. Eastern Time on Thursday, July 29, 2010. This
webcast can be accessed from CONMED’s web site at www.conmed.com. Replays
of the call will be made available through August 6, 2010.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices
and equipment for minimally invasive procedures and patient monitoring.
The Company’s products serve the clinical areas of arthroscopy, powered
surgical instruments, electrosurgery, cardiac monitoring disposables,
endosurgery and endoscopic technologies. They are used by surgeons and
physicians in a variety of specialties including orthopedics, general
surgery, gynecology, neurosurgery and gastroenterology. Headquartered in
Utica, New York, the Company’s 3,300 employees distribute its products
worldwide from several manufacturing locations.

Forward-Looking Information

This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 and relate to the
Company’s performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which
could cause actual results, performance or trends, to differ materially
from those expressed in the forward-looking statements herein or in
previous disclosures. The Company believes that all forward-looking
statements made by it have a reasonable basis, but there can be no
assurance that management’s expectations, beliefs or projections as
expressed in the forward-looking statements will actually occur or prove to
be correct. In addition to general industry and economic conditions,
factors that could cause actual results to differ materially from those
discussed in the forward-looking statements in this press release include,
but are not limited to: (i) the failure of any one or more of the
assumptions stated above, to prove to be correct; (ii) the risks relating
to forward-looking statements discussed in the Company’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2009; (iii) cyclical
purchasing patterns from customers, end-users and dealers; (iv) timely
release of new products, and acceptance of such new products by the market;
(v) the introduction of new products by competitors and other competitive
responses; (vi) the possibility that any new acquisition or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; and/or (vii) the Company’s ability to devise and execute
strategies to respond to market conditions.

                                 CONMED CORPORATION
                            Second Quarter Sales Summary

                                  Three Months Ended June 30,
                    ------------------------------------------------------

                                                                Constant
                                                                Currency
                         2009          2010       Growth         Growth
                    ------------- ------------- ------------  ------------
                           (in millions)
Arthroscopy
   Single-use       $        46.0 $        54.4         18.3%         15.4%
   Capital                   15.6          20.5         31.4%         28.8%
                    ------------- ------------- ------------  ------------
                             61.6          74.9         21.6%         18.8%
                    ------------- ------------- ------------  ------------

Powered Surgical
 Instruments
   Single-use                19.1          19.1          0.0%         -2.6%
   Capital                   14.4          16.6         15.3%         13.2%
                    ------------- ------------- ------------  ------------
                             33.5          35.7          6.6%          4.2%
                    ------------- ------------- ------------  ------------

Electrosurgery
   Single-use                17.3          18.2          5.2%          4.0%
   Capital                    5.4           5.8          7.4%          5.6%
                    ------------- ------------- ------------  ------------
                             22.7          24.0          5.7%          4.4%
                    ------------- ------------- ------------  ------------

Endoscopic
 Technologies
   Single-use                12.5          11.9         -4.8%         -6.4%
                    ------------- ------------- ------------  ------------
Endosurgery
   Single-use and
    reposable                17.3          17.1         -1.2%         -1.7%
                    ------------- ------------- ------------  ------------
Patient Care
   Single-use                17.0          17.5          2.9%          2.4%
                    ------------- ------------- ------------  ------------

Total
   Single-use and
    reposable               129.2         138.2          7.0%          5.1%
   Capital                   35.4          42.9         21.2%         18.9%
                    ------------- ------------- ------------  ------------
                    $       164.6 $       181.1         10.0%          8.1%
                    ============= ============= ============  ============




                                  CONMED CORPORATION
                                Six-Month Sales Summary

                                  Six Months Ended June 30,
                    ------------------------------------------------------

                                                                Constant
                                                                Currency
                         2009          2010        Growth        Growth
                    ------------- ------------- ------------  ------------
                           (in millions)
Arthroscopy
   Single-use       $        92.8 $       109.3         17.8%         13.0%
   Capital                   32.6          37.8         16.0%         12.6%
                    ------------- ------------- ------------  ------------
                            125.4         147.1         17.3%         12.9%
                    ------------- ------------- ------------  ------------

Powered Surgical
 Instruments
   Single-use                37.2          39.3          5.6%          0.0%
   Capital                   29.1          31.4          7.9%          4.1%
                    ------------- ------------- ------------  ------------
                             66.3          70.7          6.6%          1.8%
                    ------------- ------------- ------------  ------------

Electrosurgery
   Single-use                34.3          35.3          2.9%          0.9%
   Capital                   10.8          11.8          9.3%          6.5%
                    ------------- ------------- ------------  ------------
                             45.1          47.1          4.4%          2.2%
                    ------------- ------------- ------------  ------------

Endoscopic
 Technologies
   Single-use                24.5          23.7         -3.3%         -5.7%
                    ------------- ------------- ------------  ------------
Endosurgery
   Single-use and
    reposable                31.8          34.2          7.5%          5.7%
                    ------------- ------------- ------------  ------------
Patient Care
   Single-use                35.5          34.7         -2.3%         -3.1%
                    ------------- ------------- ------------  ------------

Total
   Single-use and
    reposable               256.1         276.5          8.0%          4.6%
   Capital                   72.5          81.0         11.7%          8.4%
                    ------------- ------------- ------------  ------------
                    $       328.6 $       357.5          8.8%          5.4%
                    ============= ============= ============  ============ 



                            CONMED CORPORATION
                    CONSOLIDATED STATEMENTS OF INCOME
                  (in thousands except per share amounts)
                                (unaudited)

                         Three months ended         Six months ended
                              June 30,                  June 30,
                       --------------------       --------------------
                         2009         2010          2009         2010
                       --------     --------      --------     --------

Net sales              $164,569     $181,086      $328,631     $357,451

Cost of sales            83,559       86,411       168,343      170,414
Cost of sales, other
 - Note A                 3,698          992         6,624        1,559
                       --------     --------      --------     --------

Gross profit             77,312       93,683       153,664      185,478
                       --------     --------      --------     --------

Selling and
 administrative          64,147       71,494       126,000      142,046
Research and
 development              7,396        6,441        15,885       14,123
Other expense (income)
 - Note B                   734          970          (602)         970
                       --------     --------      --------     --------
                         72,277       78,905       141,283      157,139
                       --------     --------      --------     -------- 

Income from
 operations               5,035       14,778        12,381       28,339

Gain (loss) on early
 extinguishment of debt       -          (79)        1,083         (79)

Amortization of debt
 discount                 1,013        1,056         2,058        2,108

Interest expense          1,767        1,771         3,255        3,520
                       --------     --------      --------     --------

Income before income
 taxes                    2,255       11,872         8,151       22,632

Provision for income
 taxes                      846        4,566         2,257        8,007
                       --------     --------      --------     --------

Net income             $  1,409     $  7,306      $  5,894     $ 14,625
                       ========     ========      ========     ========

Per share data:

  Net Income
    Basic              $    .05     $    .25      $    .20    $    .50
    Diluted                 .05          .25           .20         .50

  Weighted average
   common shares
    Basic                29,056       29,100        29,043      29,125
    Diluted              29,082       29,295        29,071      29,342

Note A — Included in cost of sales, other in the three and six months
ended June 30, 2009 are $3.7 million and $6.6 million, respectively, in
costs related to the startup of a new manufacturing facility in Chihuahua,
Mexico and the consolidation of two of the Company’s three Utica, New York
area manufacturing facilities. Included in cost of sales, other in the
three and six months ended June 30, 2010 are $1.0 million and $1.6 million,
respectively, related to the moving of additional product lines to the
manufacturing facility in Chihuahua, Mexico.

Note B — Included in other expense (income) in the three months ended June
30, 2009 is $0.7 million related to the consolidation of the Company’s
distribution activities. Included in other expense (income) in the six
months ended June 30, 2009 is a non-cash net pre-tax pension gain of $1.9
million and $1.3 million in costs related to the consolidation of the
Company’s distribution activities. Included in other expense (income) in
the three and six months ended June 30, 2010 is $1.0 million related to the
consolidation of various administrative functions in our orthopedic
division.

                            CONMED CORPORATION
                    CONSOLIDATED CONDENSED BALANCE SHEETS
                               (in thousands)
                                (unaudited)
                                   ASSETS

                                        December 31,    June 30,
                                            2009          2010
                                         ----------    ----------
Current assets:
  Cash and cash equivalents              $   10,098    $    8,490
  Accounts receivable, net                  126,162       142,801
  Inventories                               164,275       170,816
  Deferred income taxes                      14,782        13,764
  Other current assets                       10,293        13,125
                                         ----------    ----------
    Total current assets                    325,610       348,996

Property, plant and equipment, net          143,502       142,070
Deferred income taxes                         1,953         2,002
Goodwill                                    290,505       295,111
Other intangible assets, net                190,849       192,971
Other assets                                  5,994         5,595
                                         ----------    ----------
    Total assets                         $  958,413    $  986,745
                                         ==========    ==========

                     LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Current portion of long-term debt       $   2,174    $   33,208
  Other current liabilities                  76,933        73,524
                                         ----------    ----------
    Total current liabilities                79,107       106,732

Long-term debt                              182,195       170,366
Deferred income taxes                        97,916       107,091
Other long-term liabilities                  22,680        24,164
                                         ----------    ----------
    Total liabilities                       381,898       408,353
                                         ----------    ----------

Shareholders' equity:
  Capital accounts                          263,550       256,911
  Retained earnings                         325,370       339,362
  Accumulated other comprehensive
   income (loss)                            (12,405)      (17,881)
                                         ----------    ----------
    Total shareholders' equity              576,515       578,392
                                         ----------    ----------

    Total liabilities and shareholders'
     equity                              $  958,413    $  986,745
                                         ==========    ==========





                             CONMED CORPORATION
               CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
                               (in thousands)
                                (unaudited)

                                                      Six months ended
                                                          June 30,
                                                  ------------------------
                                                      2009         2010
                                                  -----------  -----------
Cash flows from operating activities:
Net income                                        $     5,894  $    14,625
Adjustments to reconcile net income
 to net cash provided by operating
 activities:
  Depreciation and amortization                        19,439       20,581
  Stock-based compensation expense                      2,090        2,082
  Deferred income taxes                                 3,129        7,239
  (Gain) loss on early extinguishment of debt          (1,083)          79
  Sale of accounts receivable to
   (collections for) purchaser                         (3,000)     (29,000)
  Increase (decrease) in cash flows from
   changes in assets and liabilities:
    Accounts receivable                                 7,999        8,718
    Inventories                                        (4,319)     (16,167)
    Accounts payable                                   (7,774)       6,100
    Income taxes payable                               (1,901)        (125)
    Accrued compensation and benefits                  (2,996)          90
    Other assets                                         (830)      (2,884)
    Other liabilities                                  (2,661)      (5,815)
                                                  -----------  -----------
Net cash provided by operating activities              13,987        5,523
                                                  -----------  -----------

Cash flows from investing activities:
  Purchases of property, plant, and
   equipment                                          (12,032)      (7,163)
  Payments related to business acquisitions              (188)      (5,157)
                                                  -----------  -----------
Net cash used in investing activities                 (12,220)     (12,320)
                                                  -----------  -----------

Cash flows from financing activities:
  Payments on debt                                     (9,519)     (14,012)
  Proceeds of debt                                      9,000            -
  Proceeds from secured borrowings, net                     -       31,000
  Repurchase of treasury stock                              -       (9,471)
  Other, net                                           (1,341)      (1,279)
                                                  -----------  -----------
Net cash provided by (used in) financing
 activities                                            (1,860)       6,238
                                                  -----------  -----------

Effect of exchange rate change on cash and cash
 equivalents                                           (1,039)      (1,049)
                                                  -----------  -----------

Net decrease in cash and cash equivalents              (1,132)      (1,608)

Cash and cash equivalents at beginning of period       11,811       10,098
                                                  -----------  -----------

Cash and cash equivalents at end of period        $    10,679  $     8,490
                                                  ===========  ===========





                           CONMED CORPORATION
        RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME
          BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT
               Three Months Ended June 30, 2009 and 2010
                (In thousands except per share amounts)
                             (unaudited)

                                                          2009      2010
                                                        --------  --------
Reported net income                                     $  1,409  $  7,306
                                                        --------  --------
New plant / facility consolidation costs included
 in cost of sales                                          3,698       992
                                                        --------  --------

CONMED Linvatec division administrative consolidation          -       970

Facility consolidation costs included in other expense
 (income)                                                    734         -
                                                        --------  --------

  Total other expense (income)                               734       970
                                                        --------  --------

Loss on early extinguishment of debt                           -        79
                                                        --------  --------

Amortization of debt discount                              1,013     1,056
                                                        --------  --------

Unusual expense (income) before income taxes               5,445     3,097

Provision (benefit) for income taxes on unusual
 expenses                                                 (1,970)   (1,125)
                                                        --------  --------

Net income before unusual items                         $  4,884  $  9,278
                                                        ========  ========

Per share data:

Reported net income
  Basic                                                 $   0.05  $   0.25
  Diluted                                                   0.05      0.25

Net income before unusual items
  Basic                                                 $   0.17  $   0.32
  Diluted                                                   0.17      0.32

Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance as
discussed in the section “Use of Non-GAAP Financial Measures” above. We
have included the amortization of debt discount in our analysis in order to
facilitate comparison with the non-GAAP earnings guidance provided in the
“Outlook” section of this and previous releases which exclude such expense.

                         CONMED CORPORATION
      RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME
         BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT
                Six Months Ended June 30, 2009 and 2010
                (In thousands except per share amounts)
                             (unaudited)

                                                          2009      2010
                                                        --------  --------

Reported net income                                     $  5,894  $ 14,625
                                                        --------  --------

New plant / facility consolidation costs included
 in cost of sales                                          6,624     1,559
                                                        --------  --------

CONMED Linvatec division administrative consolidation          -       970

Pension gain, net                                         (1,882)        -

Facility consolidation costs included in other
 expense (income)                                          1,280         -
                                                        --------  --------

      Total other expense (income)                          (602)      970
                                                        --------  --------

(Gain) loss on early extinguishment of debt               (1,083)       79
                                                        --------  --------

Amortization of debt discount                              2,058     2,108
                                                        --------  --------

Unusual expense (income) before income taxes               6,997     4,716

Provision (benefit) for income taxes on unusual
 expenses                                                 (2,538)   (1,718)
                                                        --------  --------

Net income before unusual items                         $ 10,353  $ 17,623
                                                        ========  ========

Per share data:

Reported net income
      Basic                                             $   0.20  $   0.50
      Diluted                                               0.20      0.50

Net income before unusual items
      Basic                                             $   0.36  $   0.61
      Diluted                                               0.36      0.60

Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance as
discussed in the section “Use of Non-GAAP Financial Measures” above. We
have included the amortization of debt discount in our analysis in order to
facilitate comparison with the non-GAAP earnings guidance provided in the
“Outlook” section of this and previous releases which exclude such expense.

                         CONMED CORPORATION
      IMPACT TO STATEMENT OF CASH FLOWS RELATED TO ACCOUNTING
                   CHANGE APPLIED PROSPECTIVELY
              Six Months Ended June 30, 2009 and 2010
                          (In thousands)
                            (unaudited)

                                                          2009     2010
                                                        --------  --------

Reported cash flows from operating activities           $ 13,987  $  5,523
                                                        --------  --------

Sale of accounts receivable accounting change                  -    29,000
                                                        --------  --------

Adjusted cash flows from operating activities           $ 13,987  $ 34,523
                                                        ========  ========


Reported cash flows provided by (used in) financing
 activities                                             $ (1,860) $  6,238
                                                        --------  --------

Proceeds from secured borrowings, net                          -   (31,000)
                                                        --------  --------

Adjusted cash flows provided by (used in) financing
 activities                                             $ (1,860) $(24,762)
                                                        ========  ========

Management has provided the above reconciliation of cash flow from
operations and cash flow from financing activities before the accounting
change as an additional measure that investors can use to compare operating
and financing cash flows between reporting periods. Management believes
these reconciliations provide a useful presentation of cash flows as
discussed in the section “Use of Non-GAAP Financial Measures” above.

PLEASANTON, CA–(Marketwire – July 29, 2010) –  APCO Booth #939 — As leading providers of integrated public safety solutions, Positron Front Line and its parent company Tiburon, Inc. announce a strategic partnership agreement with Intrado Inc., the leading provider of 9-1-1 technology solutions. Positron Front Line has also become Intrado’s preferred computer aided dispatch (CAD) solutions provider and will continue to deliver integrated solutions with Intrado’s call-handling applications.

As part of the agreement, Positron Front Line has committed to interoperability with Intrado’s next-generation 9-1-1 (NG9-1-1) voice and data services, ensuring that their solutions are fully compatible with approved industry standards. Through this new strategic partnership, Positron Front Line and Tiburon will work with Intrado to innovate and deliver seamless integration between Intrado’s NG9-1-1 network and value added services and the Positron Front Line VIPER CAD system, allowing NG9-1-1 capabilities and feature rich multimedia content to be accessible by public safety answering point (PSAP) operators and first responders.

NG9-1-1 represents the transformation of the legacy infrastructure of 9-1-1 based on obsolete technology first developed in the 1960s to Internet Protocol (IP) technology of the 21st century. The interoperability and integration of Positron Front Line’s CAD and Intrado’s NG9-1-1 voice and data services will be achieved using ATIS (Alliance for Telecommunications Industry Solutions) approved Emergency Services Messaging Interface (ESMI) and the Request for Assistance Interface (RFAI) standards. These standards are critical to enabling the transition from today’s legacy telecommunications systems to IP-based NG9-1-1 services in the U.S. 

“We are excited to partner with Intrado, a clear leader in next-generation 9-1-1 emergency communication services and we’re proud to be part of a partnership that will help set the standard for the future of emergency response,” said Ian Archbell, general manager of Positron Front Line. “Positron Front Line’s advanced solutions and our commitment, along with Tiburon, to improving standards and solutions for public safety agencies worldwide will further increase with this partnership.”

Intrado’s NG9-1-1 network efficiently delivers voice, text and rich media as well as hosted applications through fully-secured and redundant networks with the goal of allowing agencies and their first responders to enhance the safety, situational awareness and services they provide to their communities.

“Positron Front Line, Tiburon and Intrado are committed to supporting open standards-based technological advancements and have a shared vision about how best to enable the transformation of public safety from today’s largely legacy environments to NG9-1-1,” said Stephen Meer, chief technology officer and co-founder of Intrado. “We’re looking forward to working with Positron Front Line and Tiburon on this important integration initiative, which we believe serves the best interests of the public safety industry as a whole.”

Positron Front Line’s VIPER CAD product integrates an advanced computer aided dispatch system with flexible features, intuitive user interfaces and dynamic administrative control built on a disaster-tolerant distributed architecture. VIPER CAD enables users to manage a variety of CAD activities including tracking calls, responses and resources, changing a unit’s location and obtaining critical information such as emergency type and location. Positron Front Line’s VIPER CAD seamlessly integrates with Intrado NG9-1-1 voice and data services to provide a comprehensive emergency call-taking and dispatching capability with faster, less-costly deployment. VIPER CAD uses open standards to assure operational compatibility not only upon implementation, but throughout the future of NG9-1-1.

About Positron Front Line
As a recognized leader in advanced 9-1-1 technologies and provider of public safety solutions through hosted and traditional delivery models, Positron Front Line delivers integrated, comprehensive, cost-effective public safety solutions for dispatch, mobile communications and records management, and has more than 220 systems installed globally. A subsidiary of Tiburon, Inc., a public safety and security solution provider who serves some of the largest and most complex agencies in the world, Positron Front Line is one of the country’s leading providers of integrated public safety solutions. The company’s roots are in continuously developing, implementing and supporting automated information solutions for the public safety community since 1983. For more information, visit www.positronfrontline.com or call 877-441-4648.

About Tiburon
Established in 1980, Tiburon is the Industry-leading provider of automated public safety and security solutions to meet the demanding and complex needs of law enforcement, fire and rescue and corrections agencies. Tiburon offers fully integrated solutions including computer aided dispatch, records management, mobile data and communications, field reporting and corrections management solutions. From mission-critical conditions to daily operations, across complex multi-agency and multi-jurisdictional environments, Tiburon’s integrated solutions have set the industry standard for capability, scalability and reliability for 30 years. For more information, visit www.tiburoninc.com or call 800-428-5534.

About Intrado
In business for more than 30 years, Intrado has maintained a focus and passion for saving lives and supporting the needs of public safety. Agencies and telecommunication services providers throughout the world depend on Intrado for emergency communication services and technology. Products and services offered include emergency 9-1-1 voice call delivery, comprehensive data management, advanced call routing, emergency location and integrated call handling technologies. Intrado’s dedicated focus on emergency communications technology allows the company to continue pioneering network innovations that save lives and improve emergency response.

Click here to see all recent news from this company

MERIDIAN, ID–(Marketwire – July 29, 2010) –  MWI Veterinary Supply, Inc. (NASDAQ: MWIV) (the “Company”) announced financial results today for its third quarter ended June 30, 2010.

Highlights:

• Total revenues were $347.7 million for the quarter, 40% higher than revenues for the same period in the prior fiscal year. Of the 40% increase in total revenues, 17% was due to organic growth in the United States and 23% was related to our acquisition of Centaur Services Limited (“Centaur”). On February 8, 2010, we acquired Centaur, a supplier of animal health products to veterinarians in the United Kingdom. 
• Selling, general and administrative (“SG&A”) expenses as a percentage of total revenues were 7.9% for the quarter, compared to 9.2% for the same period in the prior fiscal year. 
• Operating income increased 38% to $15.1 million, compared to the same period in the prior fiscal year. 
• Net income increased 38% to $9.1 million, compared to the same period in the prior fiscal year. Diluted earnings per share were $0.74 compared to $0.54 in the same period of the prior fiscal year, an increase of 37%. 
• Internet sales to independent veterinary practices and producers in the United States grew by approximately 44% for the quarter compared to the same period in the prior fiscal year. Our product sales from the internet as a percentage of sales in the United States increased to 36% for the quarter as compared to 32% for the same period in the prior fiscal year.
• We generated $5.4 million in cash from operations during the quarter, and as of June 30, 2010 we had borrowings under our credit facilities of $15.9 million. 

“Our results for the quarter continue to demonstrate our strong commitment to providing excellent service and value to our customers and vendor partners,” said Jim Cleary, President and Chief Executive Officer. “Our revenue growth, expense control, earnings growth and value-added services all exceeded our expectations and I would like to thank our employees, customers and vendors for their loyalty to MWI. Also, we continue to be pleased with our integration and collaboration with the Centaur team.”

Quarter ended June 30, 2010 compared to quarter ended June 30, 2009

Total revenues increased 40% to $347.7 million for the quarter ended June 30, 2010, compared to $247.5 million for the quarter ended June 30, 2009. Of the 40% revenue growth, 23% or $57.7 million was related to the acquisition of Centaur. Excluding this acquisition, our revenues attributable to existing customers represented 43% of the growth of total revenues during the quarter ended June 30, 2010. Commissions increased 19% to $4.3 million during the quarter ended June 30, 2010, compared to $3.6 million during the quarter ended June 30, 2009. 

Gross profit increased 27% to $43.9 million for the quarter ended June 30, 2010, compared to $34.5 million for the quarter ended June 30, 2009. Gross profit was benefited by our revenue growth and the addition of Centaur. Gross profit as a percentage of total revenues was 12.6% for the quarter ended June 30, 2010, compared to 13.9% for the quarter ended June 30, 2009. Gross profit as a percentage of total revenues decreased due to the addition of Centaur because Centaur’s gross profit as a percentage of total revenues is generally lower than MWI’s, which serves to reduce the overall gross margin of the consolidated Company when compared to our results for the same period in the prior year. Vendor rebates for the quarter ended June 30, 2010 increased by approximately $540,000 compared to the quarter ended June 30, 2009.

Operating income increased 38% to $15.1 million for the quarter ended June 30, 2010, compared to $10.9 million for the quarter ended June 30, 2009. SG&A expenses increased 21% to $27.4 million for the quarter ended June 30, 2010, compared to $22.7 million for the quarter ended June 30, 2009. SG&A expenses increased primarily due to the acquisition of Centaur and our revenue growth. SG&A expenses as a percentage of total revenues improved to 7.9% for the quarter ended June 30, 2010, compared to 9.2% for the quarter ended June 30, 2009. SG&A expenses as a percentage of total revenues decreased due to the addition of Centaur because Centaur’s SG&A expenses as a percentage of total revenues are generally lower than MWI’s, which serves to reduce the overall SG&A expenses as a percentage of total revenues when compared to our results for the same period in the prior year. Additionally, we had an improvement in our allowance for doubtful accounts as a result of payments made by certain customers. 

Net income increased 38% to $9.1 million for the quarter ended June 30, 2010, compared to $6.6 million for the quarter ended June 30, 2009. Diluted earnings per share were $0.74 and $0.54 for the quarters ended June 30, 2010 and 2009, respectively, an increase of 37%. 

Nine months ended June 30, 2010 compared to nine months ended June 30, 2009

Total revenues increased 25% to $870.4 million for the nine months ended June 30, 2010, compared to $693.8 million for the nine months ended June 30, 2009. Of the 25% revenue growth, 13% or $91.3 million was related to the acquisition of Centaur. Commissions increased 18% to $12.1 million during the nine months ended June 30, 2010, compared to $10.3 million during the nine months ended June 30, 2009.

Gross profit increased by 20% to $119.5 million for the nine months ended June 30, 2010, compared to $99.8 million for the nine months ended June 30, 2009. Gross profit as a percentage of total revenues was 13.7% for the nine months ended June 30, 2010, compared to 14.4% for the nine months ended June 30, 2009. Vendor rebates for the nine months ended June 30, 2010 increased by approximately $165,000 compared to the nine months ended June 30, 2009. 

Operating income increased 36% to $40.5 million for the nine months ended June 30, 2010, compared to $29.8 million for the nine months ended June 30, 2009. SG&A expenses increased 12% to $75.4 million for the nine months ended June 30, 2010, compared to $67.4 million for the nine months ended June 30, 2009. SG&A expenses as a percentage of total revenues were 8.7% for the nine months ended June 30, 2010, compared to 9.7% for the nine months ended June 30, 2009. Included in the increase in SG&A expenses for the nine months ended June 30, 2010 are direct acquisition-related expenses of $1.1 million incurred in connection with the acquisition of Centaur. 

Net income increased 34% to $24.6 million for the nine months ended June 30, 2010, compared to $18.4 million for the nine months ended June 30, 2009. Diluted earnings per share were $1.99 and $1.49 for the nine months ended June 30, 2010 and 2009, respectively, an increase of 34%.

Our cash balance as of June 30, 2010 was $908,000 and we had $15.9 million outstanding on our credit facilities. Compared to September 30, 2009, receivables increased 30%, inventories increased 22% and accounts payable increased 26%. These increases were primarily due to the balances acquired through the acquisition of Centaur as well as our revenue growth.

Business Outlook

The Company updates its previous estimates for the fiscal year ending September 30, 2010. The Company increases its estimate that revenues will be from $1.195 billion to $1.205 billion, which represents growth of 27% to 28% compared to revenues in fiscal year 2009. The Company increases its estimate that diluted earnings per share will be from $2.58 to $2.60 per share, which represents growth of 28% to 29% compared to diluted earnings per share in fiscal year 2009. All of these estimates give effect to the acquisition of Centaur from February 8, 2010 through September 30, 2010. The Company’s previous guidance for the fiscal year ending September 30, 2010 was revenues of approximately $1.16 billion to $1.18 billion and diluted earnings per share of $2.40 to $2.45.

Conference Call

The Company will be hosting a conference call on July 29, 2010 at 11:00 a.m. eastern daylight time to discuss these results and its fiscal year 2010 business outlook in greater detail. Participants can access the conference call by dialing (877) 638-4561 and international callers can access the conference call by dialing (720) 545-0002. The conference call will also be carried live on the Company’s web site at www.mwivet.com. Audio replay will be made available through August 12, 2010 by calling (800) 642-1687 for calls within the United States or (706) 645-9291 for international calls using the passcode 89688546. The conference call will also be available on the Company’s web site, www.mwivet.com.

MWI is a leading distributor of animal health products to veterinarians across the United States of America and United Kingdom. Products MWI sells include pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, veterinary pet food and nutritional products. We market these products to veterinarians in both the companion animal and production animal markets. For more information about MWI, please visit our website at www.mwivet.com. For investor relations information please contact Mary Pat Thompson, Senior Vice President of Finance and Administration, and Chief Financial Officer at (208) 955-8930 or email [email protected].

Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those discussed in filings made by the Company with the Securities and Exchange Commission. Many of the factors that will determine the Company’s future results are beyond the ability of management to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Important assumptions and other important factors that could cause actual results to differ materially from those set forth in the forward-looking information include the impact of vendor consolidation on our business; changes in or availability of vendor rebate programs; vendor rebates based upon attaining certain growth goals; changes in the way vendors introduce products to market; exclusivity requirements with certain vendors that may prohibit us from distributing competing products manufactured by other vendors; risks associated with our international operations; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; the impact of general economic trends on our business; the recall of a significant product by one of our vendors; extended shortage or backorder of a significant product by one of our vendors; seasonality; the timing and effectiveness of marketing programs offered by our vendors; the timing of the introduction of new products and services by our vendors; the ability to borrow on our credit line, extend the terms of our credit line or obtain alternative financing on favorable terms or at all; risks from potential increases in variable interest rates; unforeseen litigation; a disruption caused by adverse weather or other natural conditions; inability to ship products to the customer as a result of technological or shipping disruptions; and competition. Other factors include changes in the rate of inflation; changes in state or federal legislation or regulation; the continued safety of the products the Company sells; and changes in the general economy. Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, we have a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of MWI Veterinary Supply, Inc.

HOUSTON, TX–(Marketwire – July 28, 2010) –  A growing demand for hand, wrist and elbow specialist Dr. David Hildreth, who once practiced exclusively at the Texas Medical Center, has prompted the growth of offices in Sugar Land and Katy. The renowned Houston orthopedic surgeon formerly of Baylor College of Medicine and The Methodist Hospital System is working to meet growing demand since joining The Richmond Bone & Joint Clinic.

Dr. Hildreth is not only available to patients in Richmond, but also now in Sugar Land and Katy. The Sugar Land office is located at 15035 SW Freeway, near Williams Trace Blvd., and the Katy office is located at 21222 Kingsland Blvd.

An original founder of the Tennis Elbow Institute of Houston and among the first Eaton-trained Dupuytren’s physicians in Houston, Dr. Hildreth has served as lead investigator in studies changing the treatment options available for many common hand, wrist and elbow conditions.

A published author who served as an associate professor at The Methodist Hospital System and Weill Medical College of Cornell University, Dr. Hildreth stays ahead of “standard of care” to bring his patients such advanced treatment options as Needle Aponeurotomy (NA) and non surgical XIAFLEX® injection therapy in the treatment of Dupuytren’s Contracture, as well as less invasive treatment for carpal and cubital tunnel syndromes, sports injuries and degenerative joint conditions.

“Practicing at a specialized orthopedic clinic such as RBJC, we have the advantage of offering the latest treatment options far more rapidly. We devote a tremendous amount of time studying the new techniques and technology within the industry to remain ahead of current ‘standards,'” said Hildreth.

“These new offices are a response to patients wanting personalized care and easier access to a higher quality of medical services in their neighborhood. We’re pleased to be able to provide them with this increased accessibility,” added Hildreth.

Featured in “Medical Advances” of Newsweek magazine and named for the fifth consecutive year among the Texas Monthly list of Super Doctors and H Texas magazine’s Top Docs, view a video of Dr. Hildreth and his staff as they provide personalized treatment and rehabilitation programs for hand, wrist and elbow patients.

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – July 28, 2010) – Sun Healthcare Group, Inc. (NASDAQ: SUNH) today
announced its operating results for the second quarter ended June 30, 2010.

Normalized results for the second-quarter period ended June 30, 2010:

--  consolidated revenues rose 1.3 percent to $474.6 million, compared to
    the same period in 2009;
    -- increased patient acuity resulted in an overall improvement in
       reimbursement rates;
    -- hospice and rehabilitation therapy businesses showed solid revenue
       growth;
--  consolidated adjusted EBITDAR was $62.8 million and adjusted EBITDAR
    margin was 13.2 percent;
--  consolidated adjusted EBITDA was $44.0 million and adjusted EBITDA
    margin was 9.3 percent;
--  diluted earnings per share from continuing operations were $0.26;
--  free cash flow was $20.6 million for the quarter;
--  results included $0.9 million of non-recurring project costs associated
    with the continued implementation of a clinical/billing platform; and
--  results have been normalized to exclude a pre-tax charge of $2.2
    million for transaction costs associated with the Separation
    transaction described in further detail later in this press release.

Commenting on the Company’s second-quarter results, Richard K. Matros,
Sun’s chairman and chief executive officer, remarked, “We have navigated
through a particularly tough time in our sector with only a slight
reduction in normalized adjusted EBITDAR and EBITDA. As we get closer to
the Oct. 1 effective date for changes in Medicare reimbursement, which
include the implementation of RUGs IV, restrictions on concurrent therapy
and elimination of the lookback period, we are bullish on the growth
opportunities that these changes provide. We still anticipate top line
softness and no growth in Medicaid rates in 2011, given the continued
budget pressures that exist in many states in which we operate. However, we
expect Medicare growth in both pricing and acuity, a decided improvement
over what we have experienced in 2010 coming off the Medicare rate
reduction in October 2009. The previously announced separation of our
operating assets and our real estate assets and the creation of the REIT
are proceeding as planned.” Matros added, “We are reaffirming our
previously announced 2010 guidance and believe that the high end of the
guidance is achievable.”

Segment Updates

On a year-over-year basis for the quarter, revenue growth in Sun’s
inpatient services business totaled $5.3 million, or 1.3 percent, due
principally to revenue growth in SolAmor, the Company’s hospice business.
SolAmor’s revenues increased from $6.3 million to $11.4 million, due to
census expansion derived from same-store census growth as well as an
October 2009 acquisition. SolAmor contributed $2.2 million of adjusted
EBITDA for the quarter and an adjusted EBITDA margin of 19.6 percent. In
the quarter, revenues from SunBridge’s nursing center operations were flat
on a year-over-year basis due to declines in nursing center customer base
and the lingering effect of the October 2009 Medicare rate reduction,
partially offset by acuity-driven rate growth. This acuity growth was
evidenced by Medicare Rehab RUG utilization of 90.9 percent, which was up
240 basis points year-over-year, and Medicare REX utilization of 45.8
percent, which was up 370 basis points year-over-year. On an overall basis,
the adjusted EBITDAR for inpatient services was $71.6 million for the
quarter, with an adjusted EBITDAR margin of 17.0 percent.

SunDance, Sun’s rehabilitation therapy services business, experienced
revenue growth of $6.5 million, or 14.7 percent, in the quarter as
non-affiliated contracts were increased by nine to a high of 335 contracts
as of June 30, 2010, and revenue per contract also increased by 10 percent.
Given the strong revenue results, adjusted EBITDA margin also expanded in
the quarter by 70 basis points, producing an 8.0 percent adjusted EBITDA
margin.

The slow economy continues to impact the demand for temporary medical
staffing across the industry. Accordingly, revenues from CareerStaff,
Sun’s medical staffing services business, were down compared to revenues in
the second quarter of 2009. Despite the decline in revenues, CareerStaff
achieved adjusted EBITDA margin growth on a sequential quarter basis of 140
basis points to 8.5 percent for the quarter.

Mr. Matros commented, “We have completed the installation of our clinical
billing platform for our nursing centers and are experiencing the benefits
of this integrated system in our daily management of the business. We
opened three new Rehab Recovery Suites® (RRS) during the quarter,
bringing our RRS count to 66 units and our RRS beds to a high of 1,632, a
6.8 percent increase in beds since the beginning of the year, with the
majority of the RRS bed growth coming in the second half of 2010 as
planned. The revenue growth we have achieved in our rehabilitation business
was solid this quarter, driven by the increase in contracts as well as the
increase in revenue per contract. Our hospice business continues to perform
consistently with our expectations, and although our medical staffing
business continues to operate in a tough environment, its adjusted EBITDA
margin remains solid.”

Conference Call

As previously announced, investors and the general public are invited to
listen to a conference call with Sun’s senior management on Thursday, July
29, 2010, at 10 a.m. Pacific / 1 p.m. Eastern, to discuss the Company’s
earnings for the second quarter of 2010.

To listen to the conference call, dial (888) 437-9315 and refer to Sun
Healthcare Group. A recording of the call will be available from 4 p.m.
Eastern on July 29, 2010, until midnight Eastern on Aug. 30, 2010, by
calling (888) 203-1112 and using access code 1833674.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing,
rehabilitative and related specialty healthcare services principally to the
senior population in the United States. Sun’s core business is providing,
through its subsidiaries, inpatient services, primarily through 166 skilled
nursing centers, 16 combined skilled nursing, assisted and independent
living centers, 10 assisted living centers, two independent living centers
and eight mental health centers. On a consolidated basis, Sun has annual
revenues of $1.9 billion and approximately 30,000 employees in 46 states.
At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25
states, of which 22,427 were available for occupancy. Sun also provides
rehabilitation therapy services to affiliated and non-affiliated centers
through its SunDance subsidiary, medical staffing services through its
CareerStaff Unlimited subsidiary and hospice services through its SolAmor
subsidiary.

In May 2010, Sun announced a plan to restructure its business by separating
its real estate assets and its operating assets into two separate publicly
traded companies (the “Separation”), subject to the approval of
stockholders and other conditions. The Separation will be accomplished by
distributing to stockholders the stock of SHG Services, Inc., a Sun
subsidiary that will own and operate the operating subsidiaries.
Substantially all of Sun’s owned real estate assets will continue to be
owned by Sun, which will, after the Separation, merge into its subsidiary,
Sabra Health Care REIT, Inc. Following this merger, SHG Services, Inc. will
change its name to Sun Healthcare Group, Inc. The common stock of both
companies is expected to trade on the NASDAQ Global Select Market. The
Separation is expected to be completed in the fourth quarter of 2010.

Forward-Looking Statement

Statements made in this release that are not historical facts are
“forward-looking” statements (as defined in the Private Securities
Litigation Reform Act of 1995) that involve risks and uncertainties and are
subject to change at any time. These forward-looking statements may
include, but are not limited to, statements containing words such as
“anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,”
“may” and similar expressions. Forward-looking statements in this release
include all statements regarding our expected future financial position and
results of operations, business strategy, the impact of reductions in
reimbursements and other changes in government reimbursement programs, the
timing and impact of the equity offering and the Separation and
transactions related thereto, growth opportunities and plans and objectives
of management for future operations. Factors that could cause actual
results to differ are identified in the public filings made by the Company
with the Securities and Exchange Commission and include changes in Medicare
and Medicaid reimbursements; the impact that any healthcare reform
legislation will have on our business; our ability to maintain the
occupancy rates and payor mix at our healthcare centers; potential
liability for losses not covered by, or in excess of, our insurance; the
effects of government regulations and investigations; the significant
amount of our indebtedness, covenants in our debt agreements that may
restrict our activities and our ability to make acquisitions, to incur more
indebtedness and to refinance indebtedness on favorable terms; our ability
to accomplish the Separation and the proposed equity and debt financings,
the impact of the current economic downturn on our business; increasing
labor costs and the shortage of qualified healthcare personnel; and our
ability to receive increases in reimbursement rates from government payors
to cover increased costs. More information on factors that could affect our
business and financial results are included in our public filings made with
the Securities and Exchange Commission, including our Annual Report on
Forms 10-K and Quarterly Reports on Form 10-Q, copies of which are
available on Sun’s web site, www.sunh.com. There may be additional risks of
which we are presently unaware or that we currently deem immaterial.

The forward-looking statements involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond our
control. We caution investors that any forward-looking statements made by
Sun are not guarantees of future performance and are only made as of the
date of this release. We disclaim any obligation to update any such factors
or to announce publicly the results of any revisions to any of the
forward-looking statements to reflect future events or developments.

Adjusted EBITDA, adjusted EBITDAR and free cash flow, as used in this press
release and in the accompanying tables, which are non-GAAP financial
measures, are each reconciled to their respective GAAP recognized financial
measures in the accompanying tables. In addition, the normalizing
adjustments to adjusted EBITDA, adjusted EBITDAR and earnings per share as
discussed in this press release and shown, together with normalizing
adjustments to other financial measures, in the accompanying tables, are
non-GAAP adjustments, and are reconciled to GAAP financial measures in the
accompanying tables.

Additional Information

In connection with the Separation, SHG Services, Inc. has filed with the
SEC a Registration Statement on Form S-1 and Sabra Health Care REIT, Inc.
has filed with the SEC a Registration Statement on Form S-4, each
containing an identical proxy statement/prospectus. The definitive proxy
statement/prospectus will be mailed to Sun stockholders. In addition, Sun
has filed a shelf registration statement on Form S-3 (including a
prospectus) relating to shares of common stock of Sun with the SEC, and
such registration statement has been declared effective. This release does
not constitute an offer to sell or a solicitation of an offer to buy shares
of Sun common stock; nor shall there be any offer, solicitation or sale of
these securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful. The offering of shares of Sun
common stock may be made only by means of a prospectus relating to the
proposed offering.

Before making any voting or investment decision, Sun stockholders and
investors are urged to read the proxy statement/prospectus, the prospectus
in the registration statement on FormS-3, and other documents filed with
the SEC carefully and in their entirety when they become available because
they will contain important information about the proposed transactions.
Stockholders will be able to obtain these documents free of charge at the
SEC’s web site at www.sec.gov. In addition, investors and stockholders of
Sun may obtain free copies of the documents filed with the SEC by
contacting Sun’s investor relations department at (505) 468-2341 (TDD
users, please call (505) 468-4458) or by sending a written request to
Investor Relations, Sun Healthcare Group, Inc. 101 Sun Avenue N.E.,
Albuquerque, N.M. 87109.

Sun and its directors and executive officers and other members of its
management and employees may be deemed to be participants in the
solicitation of proxies from the stockholders of Sun in connection with the
transactions described in this release. Information about the directors
and executive officers of Sun and their ownership of shares of Sun common
stock are set forth in the Annual Report on Form 10-K for the year ended
December 31, 2009, filed with the SEC on March 5, 2010, and in the
definitive proxy statement relating to Sun’s 2010 Annual Meeting of
Stockholders filed with the SEC on April 30, 2010. These documents can be
obtained free of charge from the sources indicated above. Additional
information regarding the interests of these participants will also be
included in the definitive proxy statement/prospectus when it becomes
available.

                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                       KEY INCOME STATEMENT FIGURES
                               CONSOLIDATED
                  (in thousands, except per share data)



                                                    For the      For the
                                                 Three Months Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------

Revenue                                           $   474,618  $   468,713

Depreciation and amortization                          12,561       11,153

Interest expense, net                                  11,776       12,465

Pre-tax income                                         17,403       18,328

Income tax expense                                      7,135        7,517

Income from continuing operations                      10,268       10,811

Loss from discontinued operations                        (295)        (715)
                                                  -----------  -----------

Net income                                        $     9,973  $    10,096
                                                  ===========  ===========


Diluted earnings per share                        $      0.22  $      0.23
                                                  ===========  ===========


Adjusted EBITDAR                                  $    60,550  $    60,201
Margin - Adjusted EBITDAR                                12.8%        12.8%

Adjusted EBITDAR normalized                       $    62,798  $    64,501
Margin - Adjusted EBITDAR normalized                     13.2%        13.8%


Adjusted EBITDA                                   $    41,740  $    41,986
Margin - Adjusted EBITDA                                  8.8%         9.0%

Adjusted EBITDA normalized                        $    43,988  $    46,286
Margin - Adjusted EBITDA normalized                       9.3%         9.9%


Pre-tax income continuing operations - normalized $    19,651  $    22,628

Income tax expense - normalized                   $     8,057  $     9,280

Income from continuing operations - normalized    $    11,594  $    13,348

Diluted earnings per share - normalized           $      0.26  $      0.30

Net income - normalized                           $    11,299  $    12,981

Diluted earnings per share - normalized           $      0.25  $      0.30

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES                

                       KEY INCOME STATEMENT FIGURES
                               CONSOLIDATED
                  (in thousands, except per share data)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------

Revenue                                           $   947,874  $   936,843

Depreciation and amortization                          25,007       21,875

Interest expense, net                                  23,752       25,191

Pre-tax income                                         35,198       37,989

Income tax expense                                     14,431       15,575

Income from continuing operations                      20,767       22,414

Loss from discontinued operations                        (596)      (2,075)
                                                  -----------  -----------

Net income                                        $    20,171  $    20,339
                                                  ===========  ===========


Diluted earnings per share                        $      0.46  $      0.46
                                                  ===========  ===========


Adjusted EBITDAR                                  $   121,319  $   121,673
Margin - Adjusted EBITDAR                                12.8%        13.0%

Adjusted EBITDAR normalized                       $   123,567  $   125,973
Margin - Adjusted EBITDAR normalized                     13.0%        13.4%


Adjusted EBITDA                                   $    83,957  $    85,095
Margin - Adjusted EBITDA                                  8.9%         9.1%

Adjusted EBITDA normalized                        $    86,205  $    89,395
Margin - Adjusted EBITDA normalized                       9.1%         9.5%


Pre-tax income continuing operations - normalized $    37,446  $    42,289

Income tax expense - normalized                   $    15,353  $    17,338

Income from continuing operations - normalized    $    22,093  $    24,951

Diluted earnings per share - normalized           $      0.50  $      0.57

Net income - normalized                           $    21,497  $    23,224

Diluted earnings per share - normalized           $      0.49  $      0.53

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                        CONSOLIDATED BALANCE SHEETS
                    (in thousands, except share data)



                                                    June 30,   December 31,
                                                      2010        2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)
                          ASSETS

Current assets:
  Cash and cash equivalents                       $   106,974  $   104,483
  Restricted cash                                      24,732       24,034
  Accounts receivable, net                            220,373      220,319
  Prepaid expenses and other assets                    18,021       21,757
  Deferred tax assets                                  69,544       68,415
                                                  -----------  -----------
    Total current assets                              439,644      439,008

Property and equipment, net                           620,999      622,682
Intangible assets, net                                 52,640       53,931
Goodwill                                              338,364      338,296
Restricted cash, non-current                              348        3,317
Deferred tax assets                                    96,180      108,999
Other assets                                            5,000        4,961
                                                  -----------  -----------
    Total assets                                  $ 1,553,175  $ 1,571,194
                                                  ===========  ===========


          LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable                                $    52,922  $    57,109
  Accrued compensation and benefits                    63,015       58,953
  Accrued self-insurance obligations, current          43,794       45,661
  Income taxes payable                                    338            -
  Other accrued liabilities                            55,507       55,265
  Current portion of long-term debt and capital
   lease obligations                                   74,827       46,416
                                                  -----------  -----------
  Total current liabilities                           290,403      263,404

Accrued self-insurance obligations, net of
 current portion                                      128,657      121,948
Long-term debt and capital lease obligations, net
 of current portion                                   588,736      654,132
Unfavorable lease obligations, net                     11,233       12,663
Other long-term liabilities                            60,692       69,983
                                                  -----------  -----------
  Total liabilities                                 1,079,721    1,122,130


Stockholders' equity:
  Preferred stock of $.01 par value, authorized
   10,000,000 shares, no shares were issued and
   outstanding as of June 30, 2010 and
   December 31, 2009                                        -            -
  Common stock of $.01 par value, authorized
   125,000,000 shares, 43,980,405 and 43,764,240
   shares issued and outstanding as of June 30, 2010
   and December 31, 2009, respectively                    440          438
  Additional paid-in capital                          657,875      655,667
  Accumulated deficit                                (183,841)    (204,012)
  Accumulated other comprehensive loss, net            (1,020)      (3,029)
                                                  -----------  -----------
                                                      473,454      449,064
                                                  -----------  -----------
    Total liabilities and stockholders' equity    $ 1,553,175  $ 1,571,194
                                                  ===========  ===========



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                      CONSOLIDATED INCOME STATEMENTS
                  (in thousands, except per share data)


                                                    For the      For the
                                                 Three Months  Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Total net revenues                                $   474,618  $   468,713
                                                  -----------  -----------
Costs and expenses:
  Operating salaries and benefits                     267,880      261,967
  Self-insurance for workers' compensation and
   general and professional liability insurance        14,558       16,809
  Operating administrative costs                       13,301       13,192
  Other operating costs                                95,884       94,530
  Center rent expense                                  18,810       18,215
  General and administrative expenses                  15,157       15,721
  Depreciation and amortization                        12,561       11,153
  Provision for losses on accounts receivable           5,040        6,293
  Interest, net of interest income of $73 and $96,
   respectively                                        11,776       12,465
  Transaction costs                                     2,248            -
  Loss on sale of assets, net                               -           40
                                                  -----------  -----------
Total costs and expenses                              457,215      450,385
                                                  -----------  -----------

Income before income taxes and discontinued
 operations                                            17,403       18,328
Income tax expense                                      7,135        7,517
                                                  -----------  -----------
Income from continuing operations                      10,268       10,811
                                                  -----------  -----------

Discontinued operations:
  Loss from discontinued operations, net of
   related taxes                                         (295)        (708)
  Loss on disposal of discontinued operations, net
   of related taxes                                         -           (7)
                                                  -----------  -----------
Loss from discontinued operations, net                   (295)        (715)
                                                  -----------  -----------

Net income                                        $     9,973  $    10,096
                                                  ===========  ===========


Basic income per common and common equivalent
 share:
  Income from continuing operations               $      0.23  $      0.25
  Loss from discontinued operations, net                    -        (0.02)
                                                  -----------  -----------
Net income                                        $      0.23  $      0.23
                                                  ===========  ===========

Diluted income per common and common equivalent
 share:
  Income from continuing operations               $      0.23  $      0.25
  Loss from discontinued operations, net                (0.01)       (0.02)
                                                  -----------  -----------
Net income                                        $      0.22  $      0.23
                                                  ===========  ===========

Weighted average number of common and
 common equivalent shares outstanding:
  Basic                                                44,233       43,851
  Diluted                                              44,352       43,960



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                      CONSOLIDATED INCOME STATEMENTS
                  (in thousands, except per share data)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Total net revenues                                $   947,874  $   936,843
                                                  -----------  -----------
Costs and expenses:
  Operating salaries and benefits                     534,918      524,878
  Self-insurance for workers' compensation and
   general and professional liability insurance        29,096       31,462
  Operating administrative costs                       25,589       25,769
  Other operating costs                               193,363      190,309
  Center rent expense                                  37,362       36,578
  General and administrative expenses                  30,424       32,471
  Depreciation and amortization                        25,007       21,875
  Provision for losses on accounts receivable          10,917       10,281
  Interest, net of interest income of $163 and
   $203, respectively                                  23,752       25,191
  Transaction costs                                     2,248            -
  Loss on sale of assets, net                               -           40
                                                  -----------  -----------
Total costs and expenses                              912,676      898,854
                                                  -----------  -----------

Income before income taxes and discontinued
 operations                                            35,198       37,989
Income tax expense                                     14,431       15,575
                                                  -----------  -----------
Income from continuing operations                      20,767       22,414
                                                  -----------  -----------

Discontinued operations:
  Loss from discontinued operations, net of
   related taxes                                         (596)      (1,760)
  Loss on disposal of discontinued operations, net
   of related taxes                                         -         (315)
                                                  -----------  -----------
Loss from discontinued operations, net                   (596)      (2,075)
                                                  -----------  -----------

Net income                                        $    20,171  $    20,339
                                                  ===========  ===========


Basic income per common and common equivalent
 share:
  Income from continuing operations               $      0.47  $      0.51
  Loss from discontinued operations, net                (0.01)       (0.05)
                                                  -----------  -----------
Net income                                        $      0.46  $      0.46
                                                  ===========  ===========

Diluted income per common and common equivalent
 share:
  Income from continuing operations               $      0.47  $      0.51
  Loss from discontinued operations, net                (0.01)       (0.05)
                                                  -----------  -----------
Net Income                                        $      0.46  $      0.46
                                                  ===========  ===========

Weighted average number of common and
 common equivalent shares outstanding:
  Basic                                                44,119       43,748
  Diluted                                              44,234       43,891



               SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (in thousands)


                                                    For the      For the
                                                 Three Months  Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Cash flows from operating activities:
 Net income                                       $     9,973  $    10,096
 Adjustments to reconcile net income to net cash
  provided by operating activities, including
  discontinued operations:
    Depreciation and amortization                      12,561       11,153
    Amortization of favorable and unfavorable
     lease intangibles                                   (474)        (474)
    Provision for losses on accounts receivable         5,125        6,294
    Loss on sale of assets, including
     discontinued operations, net                           -           53
    Stock-based compensation expense                    1,694        1,641
    Deferred taxes                                      6,755        6,345
 Changes in operating assets and liabilities, net
  of acquisitions:
    Accounts receivable                                (4,871)     (11,599)
    Restricted cash                                     3,427        1,415
    Prepaid expenses and other assets                  (1,670)        (392)
    Accounts payable                                    7,140       (1,527)
    Accrued compensation and benefits                  (4,362)      (3,907)
    Accrued self-insurance obligations                  2,805          344
    Income taxes payable                                 (290)           -
    Other accrued liabilities                          (2,457)      (5,571)
    Other long-term liabilities                        (4,144)         885
                                                  -----------  -----------
     Net cash provided by operating activities         31,212       14,756
                                                  -----------  -----------

Cash flows from investing activities:
 Capital expenditures                                 (10,656)     (13,137)
 Purchase of leased real estate                             -       (3,275)
                                                  -----------  -----------
    Net cash used for investing activities            (10,656)     (16,412)
                                                  -----------  -----------

Cash flows from financing activities:
 Principal repayments of long-term debt and
  capital lease obligations                           (16,036)      (2,075)
 Distribution to non-controlling interest                   -         (549)
 Proceeds from issuance of common stock                     -            7
                                                  -----------  -----------
    Net cash used for financing activities            (16,036)      (2,617)
                                                  -----------  -----------

Net (decrease) increase in cash and cash
 equivalents                                            4,520       (4,273)
Cash and cash equivalents at beginning of period      102,454       99,945
                                                  -----------  -----------
Cash and cash equivalents at end of period        $   106,974  $    95,672
                                                  ===========  ===========

Reconciliation of net cash provided by operating
 activities to free cash flow:

   Net cash provided by operating activities      $    31,212  $    14,756
   Capital expenditures                               (10,656)     (13,137)
                                                  -----------  -----------
    Free cash flow                                $    20,556  $     1,619
                                                  ===========  ===========

Free cash flow is defined as net cash flow provided by operating activities
less cash used for capital expenditures.  Free cash flow is used by
management to evaluate discretionary cash flow potentially available for
debt service and other financing activities.



               SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (in thousands)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Cash flows from operating activities:
 Net income                                       $    20,171  $    20,339
 Adjustments to reconcile net income to net cash
  provided by operating activities, including
  discontinued operations:
    Depreciation and amortization                      25,007       21,875
    Amortization of favorable and unfavorable
     lease intangibles                                   (948)        (876)
    Provision for losses on accounts receivable        11,139       10,281
    Loss on sale of assets, including
     discontinued operations, net                           -          575
    Stock-based compensation expense                    3,087        2,909
    Deferred taxes                                     11,691       12,520
 Changes in operating assets and liabilities, net
  of acquisitions:
    Accounts receivable                               (11,193)     (21,667)
    Restricted cash                                     2,271        9,521
    Prepaid expenses and other assets                   2,613         (238)
    Accounts payable                                    1,281       (5,063)
    Accrued compensation and benefits                   4,062          366
    Accrued self-insurance obligations                  4,842        1,251
    Income taxes payable                                  338            -
    Other accrued liabilities                              13         (825)
    Other long-term liabilities                        (5,099)       1,181
                                                  -----------  -----------
     Net cash provided by operating activities         69,275       52,149
                                                  -----------  -----------

Cash flows from investing activities:
 Capital expenditures                                 (27,714)     (25,002)
 Purchase of leased real estate                             -       (3,275)
 Proceeds from sale of assets held for sale                 -        2,174
                                                  -----------  -----------
    Net cash used for investing activities            (27,714)     (26,103)
                                                  -----------  -----------

Cash flows from financing activities:
 Principal repayments of long-term debt and
  capital lease obligations                           (36,976)     (21,687)
 Payment to non-controlling interest                   (2,025)           -
 Distribution to non-controlling interest                 (69)        (860)
 Proceeds from issuance of common stock                     -           20
                                                  -----------  -----------
    Net cash used for financing activities            (39,070)     (22,527)
                                                  -----------  -----------

Net increase in cash and cash equivalents               2,491        3,519
Cash and cash equivalents at beginning of period      104,483       92,153
                                                  -----------  -----------
Cash and cash equivalents at end of period        $   106,974  $    95,672
                                                  ===========  ===========

Reconciliation of net cash provided by operating
 activities to free cash flow:
   Net cash provided by operating activities      $    69,275  $    52,149
   Capital expenditures                               (27,714)     (25,002)
                                                  -----------  -----------
    Free cash flow                                $    41,561  $    27,147
                                                  ===========  ===========

Free cash flow is defined as net cash flow provided by operating activities
less cash used for capital expenditures.  Free cash flow is used by
management to evaluate discretionary cash flow potentially available for
debt service and other financing activities.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

            RECONCILIATION OF NET INCOME TO EBITDA and EBITDAR
                              (in thousands)



                                                    For the      For the
                                                  Three Months Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  ------------ ------------
                                                  (unaudited)  (unaudited)

Total net revenues                                $    474,618 $    468,713
                                                  ------------ ------------

Net income                                        $      9,973 $     10,096
                                                  ------------ ------------


  Income from continuing operations                     10,268       10,811

  Income tax expense                                     7,135        7,517

  Interest, net                                         11,776       12,465

  Depreciation and amortization                         12,561       11,153
                                                  ------------ ------------

EBITDA                                            $     41,740 $     41,946

  Loss on sale of assets, net                                -           40

Adjusted EBITDA                                   $     41,740 $     41,986


  Center rent expense                                   18,810       18,215
                                                  ------------ ------------

Adjusted EBITDAR                                  $     60,550 $     60,201
                                                  ============ ============

EBITDA is defined as earnings before loss on discontinued operations,
income taxes, interest, net, depreciation and amortization. Adjusted EBITDA
is defined as EBITDA before loss on sale of assets, net. Adjusted EBITDAR
is defined as Adjusted EBITDA before center rent expense. Adjusted EBITDA
and Adjusted EBITDAR are used by management to evaluate financial
performance and resource allocation for each entity within the operating
units and for the Company as a whole. Adjusted EBITDA and Adjusted EBITDAR
are commonly used as analytical indicators within the healthcare industry
and also serve as measures of leverage capacity and debt service ability.
Adjusted EBITDA and Adjusted EBITDAR should not considered as measures of
financial performance under generally accepted accounting principles. As
the items excluded from Adjusted EBITDA and Adjusted EBITDAR are
significant components in understanding and assessing finance performance,
Adjusted EBITDA and Adjusted EBITDAR should not be considered in isolation
or as alternatives to net income, cash flows generated by or used in
operating, investing or financing activities or other financial statement
data presented in the consolidated financial statements as indicators of
financial performance or liquidity. Because Adjusted EBITDA and Adjusted
EBTIDAR are not measurements determined in accordance with U.S. generally
accepted accounting principles and are thus susceptible to varying
calculations. Adjusted EBITDA and Adjusted EBITDAR as presented may not be
comparable to other similarly titled measures of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

   RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA and ADJUSTED EBITDAR
                              (in thousands)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  ------------ ------------
                                                  (unaudited)  (unaudited)

 Total net revenues                               $    947,874 $    936,843
                                                  ------------ ------------

 Net income                                       $     20,171 $     20,339
                                                  ------------ ------------


  Income from continuing operations                     20,767       22,414

  Income tax expense                                    14,431       15,575

  Interest, net                                         23,752       25,191

  Depreciation and amortization                         25,007       21,875
                                                  ------------ ------------

 EBITDA                                           $     83,957 $     85,055

  Loss on sale of assets, net                                -           40
                                                  ------------ ------------

 Adjusted EBITDA                                  $     83,957 $     85,095


  Center rent expense                                   37,362       36,578
                                                  ------------ ------------

 Adjusted EBITDAR                                 $    121,319 $    121,673
                                                  ============ ============

EBITDA is defined as earnings before loss on discontinued operations,
income taxes, interest, net, depreciation and amortization.  Adjusted
EBITDA is defined as EBITDA before loss on sale of assets , net.  Adjusted
EBITDAR is defined as Adjusted EBITDA before center rent expense.  Adjusted
EBITDA and Adjusted EBITDAR are used by management to evaluate financial
performance and resource allocation for each entity within the operating
units and for the Company as a whole.  Adjusted EBITDA and Adjusted EBITDAR
are commonly used as analytical indicators within the healthcare industry
and also serve as measures of leverage capacity and debt service ability.
Adjusted EBITDA and Adjusted EBITDAR should not considered as measures of
financial performance under generally accepted accounting principles.  As
the items excluded from Adjusted EBITDA and Adjusted EBITDAR are
significant components in understanding and assessing finance performance,
Adjusted EBITDA and Adjusted EBITDAR should not be considered in isolation
or as alternatives to net income, cash flows generated by or used in
operating, investing or financing activities or other financial statement
data presented in the consolidated financial statements as indicators of
financial performance or liquidity.  Because Adjusted EBITDA and Adjusted
EBTIDAR are not measurements determined in accordance with U.S. generally
accepted accounting principles and are thus susceptible to varying
calculations.  Adjusted EBITDA and Adjusted EBITDAR as presented may not be
comparable to other similarly titled measures of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                 For the Three Months Ended June 30, 2010
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $421,720  $30,017  $22,875  $      6  $      -  $474,618
Affiliated revenue       -   21,034      496         -   (21,530)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $421,720  $51,051  $23,371  $      6  $(21,530) $474,618
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 39,014  $ 3,921  $ 1,802  $(34,469) $      -  $ 10,268
Income tax expense       -        -        -     7,135         -     7,135
Interest, net        2,706        -        -     9,070         -    11,776
Depreciation and
 amortization       11,418      159      182       802         -    12,561
                  --------  -------  -------  --------  --------  --------

  EBITDA          $ 53,138  $ 4,080  $ 1,984  $(17,462) $      -  $ 41,740

Loss on sale of
 assets, net             -        -        -         -         -         -
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $ 53,138  $ 4,080  $ 1,984  $(17,462) $      -  $ 41,740

Center rent
 expense            18,489      118      203         -         -    18,810
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $ 71,627  $ 4,198  $ 2,187  $(17,462) $      -  $ 60,550
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $ 53,138  $ 4,080  $ 1,984  $(15,214) $      -  $ 43,988
  Normalized
   Adjusted
   EBITDAR        $ 71,627  $ 4,198  $ 2,187  $(15,214) $      -  $ 62,798


   Adjusted EBITDA
            margin    12.6%     8.0%     8.5%                          8.8%
  Adjusted EBITDAR
            margin    17.0%     8.2%     9.4%                         12.8%
        Normalized
   Adjusted EBITDA
            margin    12.6%     8.0%     8.5%                          9.3%
        Normalized
  Adjusted EBITDAR
            margin    17.0%     8.2%     9.4%                         13.2%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."


See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                  For the Six Months Ended June 30, 2010
                                (unaudited)


                           Rehabi-                      Elimina-
                           litation Medical             tion of
                 Inpatient Therapy  Staffing  Other &  Affiliated Consoli-
                 Services  Services Services  Corp Seg  Revenue    dated
                 --------  --------  -------  --------  --------  --------
Nonaffiliated
 revenue         $842,248  $ 59,381  $46,231  $     14  $      -  $947,874
Affiliated
 revenue                -    42,187      640         -   (42,827)        -
                 --------  --------  -------  --------  --------  --------
  Total revenue  $842,248  $101,568  $46,871  $     14  $(42,827) $947,874
                 --------  --------  -------  --------  --------  --------

Income (loss)
 from continuing
 operations      $ 76,771  $  7,797  $ 3,283  $(67,084) $      -  $ 20,767
Income tax
 expense                -         -        -    14,431         -    14,431
Interest, net       5,517         -       (1)   18,236         -    23,752
Depreciation and
 amortization      22,698       311      362     1,636         -    25,007
                 --------  --------  -------  --------  --------  --------

  EBITDA         $104,986  $  8,108  $ 3,644  $(32,781) $      -  $ 83,957

Loss on sale of
 assets, net            -         -        -         -         -         -
                 --------  --------  -------  --------  --------  --------

  Adjusted
   EBITDA        $104,986  $  8,108  $ 3,644  $(32,781) $      -  $ 83,957

Center rent
 expense           36,709       240      413         -         -    37,362
                 --------  --------  -------  --------  --------  --------

  Adjusted
   EBITDAR       $141,695  $  8,348  $ 4,057  $(32,781) $      -  $121,319
                 ========  ========  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA        $104,986  $  8,108  $ 3,644  $(30,533) $      -  $ 86,205
  Normalized
   Adjusted
   EBITDAR       $141,695  $  8,348  $ 4,057  $(30,533) $      -  $123,567


  Adjusted EBITDA
           margin    12.5%      8.0%     7.8%                          8.9%
 Adjusted EBITDAR
           margin    16.8%      8.2%     8.7%                         12.8%
       Normalized
  Adjusted EBITDA
           margin    12.5%      8.0%     7.8%                          9.1%
       Normalized
         Adjusted
   EBITDAR margin    16.8%      8.2%     8.7%                         13.0%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                 For the Three Months Ended June 30, 2009
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $416,451  $26,155  $26,097  $     10  $      -  $468,713
Affiliated revenue       -   18,360      563         -   (18,923)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $416,451  $44,515  $26,660  $     10  $(18,923) $468,713
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 38,804  $ 3,077  $ 2,289  $(33,359) $      -  $ 10,811
Income tax expense       -        -        -     7,517         -     7,517
Interest, net        3,111        -       (1)    9,355         -    12,465
Depreciation and
 amortization       10,118      131      232       672         -    11,153
                  --------  -------  -------  --------  --------  --------

  EBITDA          $ 52,033  $ 3,208  $ 2,520  $(15,815) $      -  $ 41,946
Loss on sale of
 assets, net             6       34        -         -         -        40
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $ 52,039  $ 3,242  $ 2,520  $(15,815) $      -  $ 41,986

Center rent
 expense            17,868      114      233         -         -    18,215
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $ 69,907  $ 3,356  $ 2,753  $(15,815) $      -  $ 60,201
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $ 56,339  $ 3,242  $ 2,520  $(15,815) $      -  $ 46,286
  Normalized
   Adjusted
   EBITDAR        $ 74,207  $ 3,356  $ 2,753  $(15,815) $      -  $ 64,501


   Adjusted EBITDA
            margin    12.5%     7.3%     9.5%                          9.0%
  Adjusted EBITDAR
            margin    16.8%     7.5%    10.3%                         12.8%
        Normalized
   Adjusted EBITDA
            margin    13.5%     7.3%     9.5%                          9.9%
        Normalized
  Adjusted EBITDAR
            margin    17.8%     7.5%    10.3%                         13.8%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                  For the Six Months Ended June 30, 2009
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $831,687  $51,671  $53,471  $     14  $      -  $936,843
Affiliated revenue       -   36,576    1,123         -   (37,699)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $831,687  $88,247  $54,594  $     14  $(37,699) $936,843
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 80,598  $ 5,966  $ 4,310  $(68,460) $      -  $ 22,414
Income tax expense       -        -        -    15,575         -    15,575
Interest, net        6,322       (2)      (1)   18,872         -    25,191
Depreciation and
 amortization       19,845      259      422     1,349         -    21,875
                  --------  -------  -------  --------  --------  --------

  EBITDA          $106,765  $ 6,223  $ 4,731  $(32,664) $      -  $ 85,055
Loss on sale of
 assets, net             6       34        -         -         -        40
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $106,771  $ 6,257  $ 4,731  $(32,664) $      -  $ 85,095

Center rent
 expense            35,872      229      477         -         -    36,578
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $142,643  $ 6,486  $ 5,208  $(32,664) $      -  $121,673
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $111,071  $ 6,257  $ 4,731  $(32,664) $      -  $ 89,395
  Normalized
   Adjusted
   EBITDAR        $146,943  $ 6,486  $ 5,208  $(32,664) $      -  $125,973


   Adjusted EBITDA
            margin   12.8%     7.1%     8.7%                          9.1%
  Adjusted EBITDAR
            margin   17.2%     7.3%     9.5%                         13.0%
        Normalized
   Adjusted EBITDA
            margin   13.4%     7.1%     8.7%                          9.5%
        Normalized
  Adjusted EBITDAR
            margin   17.7%     7.3%     9.5%                         13.4%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                Sun Healthcare Group, Inc. and Subsidiaries
                      Selected Operating Statistics
                          Continuing Operations


                            For the                     For the
                      Three Months Ended           Six Months Ended
                           June 30,                    June 30,
                    ----------------------      ----------------------
                      2010          2009          2010          2009
                    --------      --------      --------      --------
Consolidated
 Company

Revenues -
 Non-affiliated (in
 thousands)
  Inpatient
   Services         $421,720      $416,451      $842,248      $831,687
  Rehabilitation
   Therapy Services   30,017        26,155        59,381        51,671
  Medical Staffing
   Services           22,875        26,097        46,231        53,471
  Other - non-core
   businesses              6            10            14            14
                    --------      --------      --------      --------
    Total           $474,618      $468,713      $947,874      $936,843
                    ========      ========      ========      ========


Revenue Mix -
 Non-affiliated (in
 thousands)
  Medicare          $141,520  30% $137,863  29% $283,701  30% $279,739  30%
  Medicaid           190,596  40%  188,030  40%  379,920  40%  369,480  39%
  Private and Other  113,475  24%  112,784  24%  225,881  24%  227,282  24%
  Managed Care /
   Insurance          24,045   5%   25,789   6%   48,458   5%   52,198   6%
  Veterans             4,982   1%    4,247   1%    9,914   1%    8,144   1%
                    -------- ---  -------- ---  -------- ---  -------- ---
    Total           $474,618 100% $468,713 100% $947,874 100% $936,843 100%
                    ======== ===  ======== ===  ======== ===  ======== ===



Inpatient Services
 Stats

 Number of centers:      202           202           202           202
 Number of
  available beds:     22,427        22,450        22,427        22,450
 Occupancy %:           86.7%         87.8%         87.1%         88.2%


 Payor Mix % based
  on patient days:
   Medicare - SNF
    Beds                15.3%         15.7%         15.4%         16.1%
   Managed care /
    Ins. - SNF Beds      4.0%          4.1%          4.0%          4.2%
                    --------      --------      --------      --------
       Total SNF
        skilled mix     19.3%         19.8%         19.4%         20.3%
                    --------      --------      --------      --------
  Medicare              14.0%         14.3%         14.1%         14.7%
  Medicaid              62.1%         60.9%         62.1%         60.4%
  Private and Other     19.1%         20.0%         18.9%         20.0%
  Managed Care /
   Insurance             3.6%          3.8%          3.7%          3.9%
  Veterans               1.2%          1.0%          1.2%          1.0%

 Revenue Mix % of
  revenues:
   Medicare - SNF
    Beds                32.1%         32.6%         32.3%         33.2%
   Managed care /
    Ins. - SNF Beds      6.0%          6.5%          6.1%          6.6%
                    --------      --------      --------      --------
       Total SNF
        skilled mix     38.1%         39.1%         38.4%         39.8%
                    --------      --------      --------      --------
  Medicare              32.4%         32.1%         32.6%         32.7%
  Medicaid              45.2%         45.1%         45.1%         44.4%
  Private and Other     15.6%         15.6%         15.4%         15.7%
  Managed Care /
   Insurance             5.6%          6.2%          5.7%          6.2%
  Veterans               1.2%          1.0%          1.2%          1.0%


 Revenues PPD:
  LTC only Medicare
   (Part A)         $ 464.00      $ 454.44      $ 464.99      $ 452.37
  Medicare Blended
   Rate (Part A &
   B)               $ 504.18      $ 494.37      $ 503.24      $ 489.93
  Medicaid          $ 173.30      $ 171.77      $ 173.19      $ 170.25
  Private and Other $ 185.66      $ 175.27      $ 185.99      $ 176.10
  Managed Care /
   Insurance        $ 367.89      $ 376.44      $ 365.84      $ 375.17
  Veterans          $ 240.63      $ 234.73      $ 242.86      $ 227.45


Rehab contracts

 Affiliated              131           121           131           121
 Non-affiliated          335           326           335           326

 Average Qtrly
  Revenue per
  Contract          $    110      $    100      $    109      $     99
  (in thousands)



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

               NORMALIZING ADJUSTMENTS - QUARTER COMPARISON
                  (in thousands, except per share data)


                               AS REPORTED - 2nd QUARTER 2010
                 ---------------------------------------------------------
                                                  Income
                                                   from
                                                  Contin-
                                                   uing
                         Adjusted Adjusted         Opera-             Net
                 Revenue  EBITDAR  EBITDA Pre-tax  tions  Disc Ops  Income
                 -------- ------- ------- ------- ------- -------  -------

As Reported 2nd
 QUARTER 2010    $474,618 $60,550 $41,740 $17,403 $10,268 $  (295) $ 9,973
       Percent of
         Revenue             12.8%    8.8%    3.7%    2.2%   -0.1%     2.1%

Normalizing
 Adjustments:

 Separation
  transaction
  costs                 -   2,248   2,248   2,248   1,326       -    1,326
                 -------- ------- ------- ------- ------- -------  -------

Normalized As
 Reported - 2nd
 QUARTER 2010    $474,618 $62,798 $43,988 $19,651 $11,594 $  (295) $11,299
                 ======== ======= ======= ======= ======= =======  =======
       Percent of
         Revenue             13.2%    9.3%    4.1%    2.4%   -0.1%     2.4%

Diluted EPS:
      As Reported                                 $  0.23 $ (0.01) $  0.22
    As Normalized                                 $  0.26 $ (0.01) $  0.25


                               AS REPORTED - 2nd QUARTER 2009
                 ---------------------------------------------------------
                                                  Income
                                                   from
                                                  Contin-
                                                   uing
                         Adjusted Adjusted         Opera-             Net
                 Revenue  EBITDAR  EBITDA Pre-tax  tions  Disc Ops  Income
                 -------- ------- ------- ------- ------- -------  -------

As Reported - 2nd
 QUARTER 2009    $468,713 $60,201 $41,986 $18,328 $10,811 $  (715) $10,096
       Percent of
         Revenue             12.8%    9.0%    3.9%    2.3%   -0.2%     2.2%

Normalizing
 Adjustments:

 Prior periods'
  self-insurance
  costs                 -   4,300   4,300   4,300   2,537     348    2,885
                 -------- ------- ------- ------- ------- -------  -------

Normalized As
 Reported - 2nd
 QUARTER 2009    $468,713 $64,501 $46,286 $22,628 $13,348 $  (367) $12,981
                 ======== ======= ======= ======= ======= =======  =======
       Percent of
         Revenue             13.8%    9.9%    4.8%    2.8%   -0.1%     2.8%

Diluted EPS:
      As Reported                                 $  0.25 $ (0.02) $  0.23
    As Normalized                                 $  0.30 $     -  $  0.30

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

Normalizing adjustments are transactions or adjustments not related to
ongoing operations and consist of Separation transaction costs and prior
periods' self-insurance costs.

Since normalizing adjustments are not measurements determined  in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations and interpretations, the information
presented herein may not be comparable to other similarly described
information of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

            NORMALIZING ADJUSTMENTS - YEAR TO DATE COMPARISON
                  (in thousands, except per share data)


                               AS REPORTED - SIX MONTHS 2010
                 ---------------------------------------------------------
                                                 Income
                                                  from
                                                 Contin-
                                                  uing
                        Adjusted Adjusted         Opera-             Net
               Revenue   EBITDAR  EBITDA Pre-tax  tions   Disc Ops  Income
               -------- -------- ------- ------- -------- -------  -------

As Reported -
 Six Months
 2010          $947,874 $121,319 $83,957 $35,198 $20,767 $   (596) $20,171
     Percent of
       Revenue              12.8%    8.9%    3.7%    2.2%    -0.1%     2.1%

Normalizing
 Adjustments:

 Separation
  transaction
  costs               -    2,248   2,248   2,248   1,326        -    1,326
               -------- -------- ------- ------- ------- --------  -------

Normalized As
 Reported - Six
 Months 2010   $947,874 $123,567 $86,205 $37,446 $22,093 $   (596) $21,497
               ======== ======== ======= ======= ======= ========  =======
     Percent of
       Revenue              13.0%    9.1%    4.0%    2.3%    -0.1%     2.3%

Diluted EPS:
    As Reported                                  $  0.47 $  (0.01) $  0.46
  As Normalized                                  $  0.50 $  (0.01) $  0.49


                               AS REPORTED - SIX MONTHS 2009
                 ---------------------------------------------------------
                                                 Income
                                                  from
                                                 Contin-
                                                  uing
                        Adjusted Adjusted         Opera-             Net
               Revenue   EBITDAR  EBITDA Pre-tax  tions   Disc Ops  Income
               -------- -------- ------- ------- -------- -------  -------

As Reported -
 Six Months
 2009          $936,843 $121,673 $85,095 $37,989 $22,414 $ (2,075) $20,339

     Percent of
       Revenue              13.0%    9.1%    4.1%    2.4%    -0.2%     2.2%

Normalizing
 Adjustments:

 Prior periods'
  self-insurance
  costs               -    4,300   4,300   4,300   2,537      348    2,885
               -------- -------- ------- ------- ------- --------  -------

Normalized As
 Reported - Six
 Months 2009   $936,843 $125,973 $89,395 $42,289 $24,951 $ (1,727) $23,224
               ======== ======== ======= ======= ======= ========  =======
     Percent of
       Revenue              13.4%    9.5%    4.5%    2.7%    -0.2%     2.5%

Diluted EPS:
    As Reported                                  $  0.51 $  (0.05) $  0.46
  As Normalized                                  $  0.57 $  (0.04) $  0.53

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

Normalizing adjustments are transactions or adjustments not related to
ongoing operations and consist of Separation transaction costs and prior
periods' self-insurance costs.

Since normalizing adjustments are not measurements determined  in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations and interpretations, the information
presented herein may not be comparable to other similarly described
information of other companies.

NASHVILLE, TN–(Marketwire – July 28, 2010) – In conjunction with Vanguard Health Systems,
Inc.’s 2010 Fourth Quarter and Year-End Earnings press release, you are
invited to listen to its conference call that will be broadcast live over
the Internet with senior management of Vanguard discussing the operating
results.

WHAT:    Vanguard Health Systems, Inc.'s 2010 Fourth Quarter and Year-End
         Earnings Conference Call on the Web

WHEN:    Thursday, August 26, 2010 at 11:00 a.m. Eastern time

WHERE:   http://www.vanguardhealth.com or
         http://www.visualwebcaster.com/event.asp?id=71303

HOW:     Live over the Internet -- Simply log on to the web at one of the
         addresses above.  If you connect through www.vanguardhealth.com,
         select the "Latest News" link on the Investor Relations page.

Vanguard Health Systems, Inc. will release its 2010 fourth quarter and
year-end operating results on Wednesday, August 25, 2010, after 4:00 p.m.
Eastern time. The Company’s earnings press release will be posted under
the “Latest News” link on the Investor Relations page of the Company’s web
site www.vanguardhealth.com.

Vanguard Health Systems, Inc. owns and operates 15 acute care hospitals and
complementary facilities and services in Chicago, Illinois; Phoenix,
Arizona; San Antonio, Texas and Massachusetts.

If you are unable to participate during the live Webcast, the call will be
archived on our web site www.vanguardhealth.com. To access the replay,
click on the “Latest News” link on the Investor Relations page of our web
site.

LOS GATOS, CA–(Marketwire – July 28, 2010) –  SCI Solutions^®, the premier Access Management solution provider for healthcare, today announced the release of a new version (v33) of its powerful, rules-based, enterprise scheduling solution, Schedule Maximizer®.

Schedule Maximizer (v33) features numerous updates, including enhanced scheduling functionality that incorporates insurance verification/eligibility rules affecting consumer driven health plans. The revamped Encounter Module, Multi-entity Rules and Worklist features further simplify and streamline a hospital’s pre-registration/registration processes.

Additionally, Schedule Maximizer’s reporting capabilities have been expanded to include a new report that provides the total number of patients that are scheduled for a particular date or date range. This report is a quick and efficient method to assist in Registration clerk staffing needs for a facility and/or a particular location/clinic in that facility.

According to Kristy Roesner, SCI’s SVP of Product Development, “The enhancements in Schedule Maximizer (v33) reflect SCI’s position as innovators in the Healthcare Information Technology arena.” She continued, “We are proud of this version’s updates as they represent significant enhancements that expand its overall capabilities as an insurance verification and pre-registration process improvement tool.”

SCI Solutions, through its Software as a Service (SaaS) model, provides a full complement of front-end patient access and revenue cycle tools that include comprehensive enterprise scheduling and registration, sophisticated workflow to manage a hospital’s orders, scheduling and pre-encounter revenue cycle requirements. Additionally, SCI provides customer self-service solutions that help physicians and patients interact seamlessly with your organization for all their access-related needs. SCI’s Access Management offerings fall into the following categories:

• Order Facilitator^®
• Schedule Maximizer^®
• Revenue Accelerator^®
• Consumer Portal
• Provider Portal

About SCI Solutions

SCI Solutions is transforming healthcare Access Management with web-based products and services that facilitate the efficient and secure exchange of clinical and financial information between patients, physicians and healthcare facilities. SCI provides a variety of products and self-service portals that help physicians and patients interact easily and at their convenience for many of their access-related needs. From a hospital’s clinical departments, to its financial executives, to its physicians SCI improves their effectiveness while making the patient’s service experience first class.

Founded in 1999, SCI Solutions is headquartered in Los Gatos, Calif. with additional offices in Tucson, Ariz., Pensacola, Fla. and employees throughout the United States. For more information about SCI Solutions, visit www.scisolutions.com.

Click here to see all recent news from this company

NATICK, MA–(Marketwire – July 28, 2010) –  To ensure downtime access to current patient data after moving to electronic medical records (EMRs) and electronic medication administration records (eMARs), Hancock Regional Hospital in Greenfield, IN implemented NetSafe, Interbit Data‘s downtime protection and business continuance solution. NetSafe downloads up-to-the-minute patient data and records from the hospital’s MEDITECH Healthcare Information System (HCIS) and provides access to it from local machines, allowing clinicians to obtain the information they need where they need it whenever the system or network goes down. With NetSafe, critical patient data is always available and the hospital assures patient safety and the delivery of uninterrupted care.

“NetSafe is a terrific safety net if the HCIS, a server or the network goes down,” states Doug Hogue, information analyst at Hancock Regional Hospital. “It’s one of those tools we hope to never have to use, but if and when we do need to rely on it, we have complete trust it will perform superbly. With NetSafe, we have peace of mind knowing that the latest eMARs and other important patient information are in a location that we can access when that information is needed.”

A one-minute video on the downtime protection and business continuance benefits of NetSafe is available at: http://interbitdata.com/business-continuance/netsafe/

Using NetSafe, Hancock Regional Hospital downloads updates of the eMARs every hour to ensure that clinicians can obtain the most up-to-date medication information on their patients whenever the system is unavailable. Electronic physician orders are updated twice per day and in PDF format, allowing staffers at registration desks to bring up and view the orders easily. Patient profiles, surgery schedules and out-patient schedules are also downloaded and updated. Physicians’ practices use NetSafe as well to back up their schedules. 

Since Hancock Regional Hospital started using NetSafe in 2007, it has had four planned downtimes due to MEDITECH updates. It has had no unplanned downtimes as yet. 

“If an unplanned downtime were to happen, we’re confident that we’re ready,” confirms Hogue. “NetSafe has performed flawlessly during the downtimes Hancock Regional Hospital has experienced so far, providing clinicians with whatever information they needed during those times.”

Over the three-plus years of using NetSafe, Hancock Regional Hospital’s experience with it has been nothing but positive.

“I love it, it’s a great product,” affirms Hogue. “NetSafe is easy to use, and other than normal server maintenance, I don’t need to do anything to it.”

More information on NetSafe can be obtained at http://interbitdata.com/business-continuance/netsafe/.

About Hancock Regional Hospital
Hancock Regional Hospital in Greenfield, IN is a full-service primary care facility serving the residents in east-central Indiana. The hospital offers a state-of-the-art surgery department, 24-hour emergency services, progressive and critical care, occupational health, a transitional care unit, a total oncology program, and comprehensive inpatient and outpatient services, including the more specialized Diabetes Center and Center for Wound Healing.

About Interbit Data
Founded in 1997 and named to the 2009 Inc. 5000 list of America’s fastest growing companies, Interbit Data helps healthcare organizations deliver better, more consistent patient care with secure, reliable and cost-effective software solutions that improve operational efficiency. The company’s information distribution products deliver information securely over the Internet in multiple formats, such as fax, print, email, encrypted file or HL7 message format, and integrate it easily into physicians’ practice EMRs. Interbit Data’s business continuance products give healthcare providers continuous access to patient data in the event of a network or system outage. Interbit Data products are used by more than 650 MEDITECH^® customers worldwide. For more information about Interbit Data and its NetSolutions products, visit the company Website at www.interbitdata.com.

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – July 28, 2010) – DiaMedica Inc., (TSX VENTURE:DMA) today announces the initiation of the Company’s autoimmune program with the success of DM-99 for the treatment of rheumatoid arthritis and other autoimmune diseases.

DM-99 was found to reduce joint swelling by up to 90% (p<0.001) in a collagen induced animal model of rheumatoid arthritis (RA) during the peak of the disease. A single dose of the protein DM-99 administered at the first signs of RA symptoms delayed the onset and severity of the disease. Furthermore, treatment given every forth day appears to have halted the autoimmune attack altogether. 

“We believe that DM-99 is able to activate or increase the number of regulatory T cells (Tregs), which plays a vital role in suppressing the autoimmune attack in a wide range of autoimmune diseases,” commented Dr. Mark Williams, DiaMedica’s Vice President Research.

In a delayed hypersensitivity model, skin inflammation was reduced by 67% (p<0.05) and could be prevented for up to 14 days following a single administration of DM-99. DM-99 also delayed skin graft rejection by several days (p<0.05).

“Based on the ability of DM-99 to modulate the autoimmune attack in several autoimmune diseases, we will be starting a study shortly to determine if our more active form of DM-99, DM-199, can halt or slow the autoimmune attack in type I diabetes. DM-199, may be the only compound that both proliferates beta cells and protects them against the autoimmune attack in type I diabetes,” stated Rick Pauls, President and CEO of DiaMedica.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders. The Company’s type 2 diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products, DM-71 and DM-99, have previously demonstrated human efficacy in lowering blood sugar levels in people diagnosed with type 2 diabetes based on this novel nerve signaling mechanism.

DiaMedica has expanded its DM-199 recombinant protein program into neurological and autoimmune disorders. The Company has demonstrated that DM-99, the naturally occurring form of DM-199, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 28, 2010) –

TO: Investors, Analysts and Journalists

WHAT: NicOx S.A. will release its 2010 half year financial results on July
30 before the opening of the market trading in France and will host a
conference call at 3:00 pm CET.

WHO: Michele Garufi, Chairman and CEO

Eric Castaldi, Chief Financial Officer

Gavin Spencer, VP Business Development

WHEN: Friday July 30 – 3:00 pm CET (2:00 pm UK – 9:00 am EST)

Phone number: +44 (0)20 7138 0845 or +1 212 444 0895 (for conference call
and Q&A session).

A presentation will be available on NicOx’s website: www.nicox.com.

A replay of the conference call will be available from July 30 at 6:00 pm
CET until August 6 midnight. To listen to the replay, dial +44 (0) 20 7111
1244 or +1 347 366 9565 – Access code: 3771435?

Thanks to confirm your participation to Irène Lalande, Investor and
Media Relations Coordinator. Tel: +33 (0)4 97 24 53 11 / [email protected]

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This information is provided by HUGIN

SALT LAKE CITY, UT–(Marketwire – July 28, 2010) –  AdvancedMD^® Software, Inc., the leader in all-in-one, web-based practice management, electronic health record (EHR), and billing applications for medical practices and medical billing services, today announced that PhySource Solutions, Inc., an AdvancedMD AdvancedBiller^® partner, has achieved two significant milestones in client service and company growth. On average, over the past 12 months the company’s new clients have reduced outstanding accounts receivable balances considered uncollectible from 30% to 2%. This caliber of results has fueled more than 100% growth in the company’s client list over the past year.

With the prolonged economic downturn, PhySource Solutions has seen many medical group clients struggle to keep accounts receivable within acceptable limits. Typical new clients have more than 30% of their receivables in the 90-day or greater category, which is considered mostly uncollectible. After only six months with PhySource Solutions, new medical practice clients see accounts receivable numbers come into line with MGMA industry benchmarks. PhySource clients realize on average 80% of claims in the current category (within 30 days) and only 10% at 90 days or more.

“Bringing accounts receivable in line is an exciting thing for clients, particularly when they see the impact it can have on revenues and profitability,” said Zina Kacha, director of business relations for PhySource Solutions. “In a scenario like this, clients regularly see at least a 15 percent improvement in revenues and profits.” PhySource founders Patricia Rosbrook and Kacha each have more than 25 years of experience in medical billing, financial analysis, consulting and executive management in a variety of healthcare related companies.

Largely as a result of the magnitude of payment improvement PhySource regularly achieves for clients, the company recently signed a new contract to provide billing services to San Diego Heart and Vascular, a seven provider Cardiology group serving the San Diego region. “The number one reason we switched [to PhySource Solutions] was that Dr. Salami’s trial EOB reports came in showing line after line of ‘paid’ instead of the multiple zeros we saw under the previous system,” said Mary Augenbaugh, practice administrator for San Diego Heart and Vascular.

As a participant in the AdvancedBiller partner network, PhySource Solutions runs its revenue management service on the AdvancedMD Software-as-a-Service platform, featuring a continuously updated payer rules engine, connectivity to more than 1,400 payers and instant software updates. In a large measure due to these AdvancedMD automation tools for claims management and the system’s robust reporting capabilities, PhySource was able to double its business last year and expects to double again next year. By avoiding stacks of paper, unwieldy filing systems, and tedious work in tracking down details, the firm has built a highly effective claims management system that can be quickly scaled up to handle the significant growth PhySource is experiencing.

“AdvancedMD is quality backed by functionality that equals manageability,” said Kacha. “It allows us to compile, maintain and track the mountains of data endemic to our industry in a way that I’ve never seen before. It’s the WOW of medical billing software.”

“AdvancedMD has made a corporate commitment that we will not compete with our billing service provider customers,” said Bill Stone, vice president and general manager of AdvancedMD Billing Services Partner Division. “Our relationship with PhySource Solutions is a prime example of this philosophy in action. We couldn’t be more pleased with their growth and success, and we remain committed to helping them grow their client base.” The AdvancedBiller program not only provides medical billing services with a leading technology platform, it provides lead generation opportunities to partners and sales support to help the billing service accelerate sales.

AdvancedMD Resources

• Learn more about PhySource Solutions: http://advancedmd.com/resources/medical-billing-software-case-study/
• Learn about the AdvancedBiller program: www.advancedbiller.com
• Learn about SaaS-based medical office software

About PhySource Solutions, Inc.

PhySource Solutions is a dynamic company located in San Diego, California. PhySource Solutions uses extensive surgical coding and medical billing knowledge to deliver comprehensive Revenue Cycle Management Services to its providers. The company has deep specialty specific experience and proficiencies for cardiology surgeon groups, helping their providers optimize their bottom line by providing a fully integrated Revenue Cycle Management service that includes surgical coding, medical billing, front-end training and financial analysis and reports. For more information, please visit www.physourcesolutions.com.

About AdvancedMD Software

AdvancedMD provides a market leading Software-as-a-Service (SaaS) electronic health record (EHR) and practice management (PM) software platform delivered to more than 10,000 providers and 300 medical billing service providers nationwide. As a complete Medical Practice Optimization solution, the product combines the clinical with the financial to improve workflow and revenue capture. The AdvancedMD solution includes a certified EHR, patient portal, scheduling, electronic eligibility verification, electronic prescribing, and mobile access capabilities for the practice. It provides sophisticated, efficient claims processing, denial tracking and revenue management for the billing professional. Processing more than 1M claims per month through its clearinghouse, the company is able to identify payer rule changes quickly and continuously adjust the software to reflect those changes, yielding first-pass claim acceptance rates of 95 percent or better, compared to the national average of 70 percent. For more information, please visit www.advancedmd.com.

*AdvancedBiller is a registered trademark of AdvancedMD

BETHESDA, MD–(Marketwire – July 28, 2010) –  GetWellNetwork, Inc., the leader in interactive patient care, today welcomed new customer Adventist Medical Center-Hanford located in Hanford, California. The hospital will implement the GetWellNetwork solution hospital-wide and go live this fall. 

Adventist Health/Central Valley Network is the first organization in the region to offer the GetWellNetwork interactive patient care system to its patients. The GetWellNetwork solution enables clinicians and hospital staff to more actively engage patients and their families in the care process by using the bedside TV to provide them with information specific to their condition, medication, treatment and discharge procedures.

“GetWellNetwork goes beyond patient entertainment to create an environment that empowers patients and their families to be truly involved in their care,” said Kristen Johnson, MHA, BSN, RN, vice president of Patient Care Services, Adventist Medical Center-Hanford. “Hospitals that have implemented the GetWellNetwork solution have raised patient satisfaction, improved patient safety and quality, and reduced hospital costs. We are excited to offer the GetWellNetwork system in our hospital.”

In the first phase, the hospital will offer patients satellite TV channels, HBO movies, 74 games, high quality Internet browsing capabilities, as well as a variety of hospital information and resources such as visiting hours, cafeteria menu, maps, chaplain services, hospital services and staff information.

In the second phase of the implementation, beginning in 2011, the hospital will look to offer additional features such as:

• Personalized information on the home screen such as the patient’s primary physician, the nurse on duty and other clinical providers, in English and Spanish;

• Patient Pathways to actively send messages to patients to complete medication teaching, answer patient satisfaction surveys, learn about discharge instructions, and more; 

• Patients may also be asked to “nominate” their favorite nurse or doctor through an electronic comment card prior to discharge; and

• The hospital expects to implement the pain management capability that prompts patients to rate their level of pain at set intervals, and program the system to turn on healing video content such as soothing nature scenes.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

DUBAI, UNITED ARAB EMIRATES–(Marketwire – July 28, 2010) – A survey published today by a prominent Medical Tourism consultant has revealed that 94% of medical tourism industry insiders believe their sector of the industry has yet to reach its full potential. The report, which can be viewed on-line at www.DrPrem.com, shows that confusion, a lack of information and fear about complications following surgery are the main reasons for patient reluctance to cross international borders for health services.

“The medical tourism industry is going through an exciting phase where international and intra-regional activities are taking places within this sector of the health market,” said Dr. Prem Jagyasi, architect of the survey and an experienced consultant in the healthcare travel sector. “The responses received clearly revealed that there is an overwhelming perception among industry leaders that there is so much more that can be achieved,” he added.

The findings are particularly interesting as more than 35 countries were identified as important medical tourism destinations. Of the 35 countries, India was ranked as the number one popular destination, with Thailand and Singapore positioned at second and third places respectively. The United States had a surprise ranking at number four.

“The Asian and Far Eastern countries are well-established medical tourism destinations, so the top three placing were expected,” said Dr. Jagyasi. “The United States came in at number four, which clearly indicate Medical Tourism is not all about low price affairs. The quality of healthcare services at a destination is deemed to be of utmost importance. Latin American and European countries were in the top ten, indicating that medical tourism is not dominated by one continent or geography – it’s a truly global industry” added Dr Prem Jagyasi who is also Honorary Chief Strategy Officer of Medical Tourism Association, world’s biggest non-profit organization of this particular industry, based in Florida US with representative office across the world.

The purpose of the health tourism survey, according to Dr. Jagyasi, was to gain valuable insights into aspects of medical tourism from professionals who are closely involved with the industry. Ninety-five per cent of the survey’s participants identified themselves as being either directly or indirectly involved with healthcare travel in the scope of their work and the resulting information supplied by these insiders revealed many important facts concerning this specialised sector; including its terms, trends, status, opportunities and challenges. The knowledge gleaned from the survey will be used to promote this sector of the healthcare industry and will provide important content for a soon-to-be published guidebook for consumers who are considering undertaking treatment abroad.

“One of the survey questions enquired why the respondents thought that there may be a reluctance in some consumers to participate in healthcare tourism and the main responses we received were that they may have concerns about complications, experience confusion over aspects of available services, be uninformed and find the option complicated,” said Dr. Jagyasi. “This is important information, as it clearly shows that education is a vital component in allowing us to facilitate medical tourism to reach its greatest potential. If we can allay people’s fears about foreign treatments and guide potential health tourists with information on what to expect and important advice on visa and travel issues, then we will be providing a vital service and as well as giving a welcome boost to the region’s health sector,” he added. 

Hence, Dr Prem Jagyasi has taken initiative to publish a guidebook. He has high hopes that it will become a handy reference tool for those wanting to know more about the intricacies of travelling across borders for healthcare services. The book is the latest achievement in his specialist interest in medical tourism and he has visited more than 20 countries and spoken at 30 international congresses relating to this sector of the healthcare industry. “Medical tourism can offer huge benefits in terms of quality of service and its affordability, in fact, the survey revealed that industry leaders view these as being its key drivers,” he said. “The industry is set to grow enormously over the next two decades as more and more destinations open up to patients from overseas,” he added.

The medical tourism survey was conducted on-line and contained questions that had been developed over a six month period and based on intensive research. The qualitative assessment was sent to medical tourism professionals in North America, South America, Africa, Europe, the Middle East and Gulf regions, Asia and the Far East. It found that medical tourism facilitators are in a prime position to capitalise on the promising opportunities offered by this sector of the health market; with 88% of respondents agreeing that role of facilitator – those agencies providing health-related travel services – are either important or very important in this segment.

Selected Observations from Survey Results (Download complete report from www.DrPrem.com )

• The preferred term from respondents for this particular sector of the healthcare industry is ‘Medical Tourism’, with 35% selecting this option. ‘Global Healthcare’ was the next most popular term at 22%, with ‘Health Tourism’ running a close third at 21%. “Medical Travel’ was identified by 10% of respondents as their preferred description, with ‘Healthcare Travel’ and ‘Value Medical Travel’ both at 6%.

• 35 countries in total were identified as being medical tourism destinations; which were (in alphabetical order: Argentina, Australia, Belgium, Brazil, Caribbean, China, Costa Rica, Cuba, France, Germany, Hungary, India, Israel, Japan, Jordan, Malaysia, Mexico, Morocco, New Zealand, Panama, Philippines, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Tunisia, Turkey, UAE, UK and USA.

• India, Thailand and Singapore were ranked first, second and third as the most popular medical tourism destinations respectively. The United States was placed at number four.

• 94% of respondents agreed with a statement that medical tourism was yet to reach its full potential.

• The four most popular reasons given for why patients travel abroad to receive medical treatment were ‘Affordability (costly in home country)’ at 88%, ‘Accessibility (waiting period is high)’ at 66% ‘Better quality (care and support services are better quality than the home country) at 38% and ‘Availability (not available in home country) at 46%.

• The four most popular reasons given for patients being unwilling to avail themselves of treatment abroad were ‘Concern about complications’ at 50%, ‘Confusion’ at 46%, patients being ‘Uninformed’ at 44% and finding the option ‘Complicated’ at 39%

• The top four challenges to the medical tourism industry were identified as being ‘Accessing reliable information’ at 59%, ‘Too many newcomers jumping on the medical tourism bandwagon, not experienced or understanding of the industry’ at 54%, ‘Lack of pre and post operative care arrangements at 52% and ‘Complicated intra-country laws and legal procedures’ at 49%.

• The top three reasons identified that are essential components of a good medical tourism destination were ‘Quality standards of healthcare and wellness services’ which was marked by 51% of respondents, followed by ‘Accessibility of the destination’ at 30% and ‘Technology, facilities & specialisations available’ at 27%.

• The survey takers were asked why they thought Medical tourism was a new ‘buzzword’ (or more accurately a ‘buzz phrase’). Fifty-six per cent (56%) agreed that it was ‘Because increasing numbers are travelling for healthcare’, with almost the same percentage (55%) also agreeing that it was ‘Because medical tourism benefits a cross section, including governments insurance companies, travel/tourism, healthcare and facilitators’. Fifty-seven per cent (57%) agreed that it was ‘Because it offers value for money’ and 46% said that it was ‘Because big hospitals are promoting it’. 

• The role of facilitators in the industry was deemed by the respondents to be significant (an explanation of facilitators being that they arrange medical tourism either in part or in whole for health tourists). Sixty-one per cent (61%) said that facilitators were ‘Very important’, 27% said that they were ‘Important’, 10% regarded them as ‘Optional’ and 2% said that they were ‘Not important’.

About ExHealth:

Motivated by a creative vision and committed to an innovative mission, ExHealth offers a comprehensive array of tailor-made, media-related healthcare services, encompassing Marketing, Public Relations, Conference and Event Management, Design & Publication, Healthcare Tourism Consulting and Medical Management Consulting, all of which are located under one roof at Dubai HealthCare City. ExHealth’s key concern is to perform and execute incomparable solutions for healthcare organisations across all sectors of the industry. Aiming to achieve and surpass its customers’ stated goals, ExHealth is focused on ensuring that its clients’ business has the edge in today’s competitive market place.

About Dr Prem Jagyasi

Dr Prem Jagyasi is a successful entrepreneur and experienced strategic professional. He is a renowned chartered management, healthcare marketing and medical tourism consultant responsible for providing high-profile consultancy services to both government authorities and private healthcare organisations. Dr. Prem Jagyasi’s commitment to developing medical tourism has seen him become a leading figure in the international healthcare tourism world.

Currently, Dr Prem Jagyasi is MD & CEO of ExHealth; a Dubai Health Care City-based firm engaged in offering multi-dimensional healthcare solutions across the international domain. He also serves the Medical Tourism Association — a non-profit organization based in USA – as Honorary Chief Strategy Officer. He is also the Chief Editor of UAE’s leading health magazine, HealthFirst, which is published in association with one of the region’s leading English language daily newspapers.

Direct Download Link

http://www.drprem.com/Medical_Tourism_Research_and_Survey_Report_by_Dr_Prem_Jagyasi.pdf